WO2015069791A1 - Method for preparing ffpe quality control material with bulking agent - Google Patents
Method for preparing ffpe quality control material with bulking agent Download PDFInfo
- Publication number
- WO2015069791A1 WO2015069791A1 PCT/US2014/064162 US2014064162W WO2015069791A1 WO 2015069791 A1 WO2015069791 A1 WO 2015069791A1 US 2014064162 W US2014064162 W US 2014064162W WO 2015069791 A1 WO2015069791 A1 WO 2015069791A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- bulking agent
- test
- ffpe
- tissue
- Prior art date
Links
- 239000004067 bulking agent Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims description 105
- 239000000463 material Substances 0.000 title abstract description 67
- 238000003908 quality control method Methods 0.000 title abstract description 29
- 238000003556 assay Methods 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 219
- 238000012360 testing method Methods 0.000 claims description 111
- 210000003743 erythrocyte Anatomy 0.000 claims description 53
- 239000003550 marker Substances 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 108700011259 MicroRNAs Proteins 0.000 claims description 9
- 239000002679 microRNA Substances 0.000 claims description 7
- 108091093105 Nuclear DNA Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 abstract description 10
- 238000012795 verification Methods 0.000 abstract description 5
- 238000010200 validation analysis Methods 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 111
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000012188 paraffin wax Substances 0.000 description 43
- 239000000523 sample Substances 0.000 description 42
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 35
- 239000000499 gel Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- 230000035772 mutation Effects 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 21
- 230000001413 cellular effect Effects 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102100030708 GTPase KRas Human genes 0.000 description 16
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 16
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 16
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000002250 absorbent Substances 0.000 description 10
- 230000002745 absorbent Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102200006538 rs121913530 Human genes 0.000 description 10
- -1 polypropylene Polymers 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 239000000834 fixative Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 206010069755 K-ras gene mutation Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 108010022394 Threonine synthase Proteins 0.000 description 5
- 102000005497 Thymidylate Synthase Human genes 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 102200006531 rs121913529 Human genes 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- 102100025684 APC membrane recruitment protein 1 Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100028914 Catenin beta-1 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100028650 Glucose-induced degradation protein 4 homolog Human genes 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 101000719162 Homo sapiens APC membrane recruitment protein 1 Proteins 0.000 description 2
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 2
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 2
- 101001058369 Homo sapiens Glucose-induced degradation protein 4 homolog Proteins 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000078511 Microtome Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 102200006532 rs112445441 Human genes 0.000 description 2
- 102200048928 rs121434568 Human genes 0.000 description 2
- 102200048955 rs121434569 Human genes 0.000 description 2
- 102200048795 rs121913428 Human genes 0.000 description 2
- 102200048929 rs121913444 Human genes 0.000 description 2
- 102200048951 rs121913465 Human genes 0.000 description 2
- 102200006537 rs121913529 Human genes 0.000 description 2
- 102200006540 rs121913530 Human genes 0.000 description 2
- 102200006541 rs121913530 Human genes 0.000 description 2
- 102200048796 rs28929495 Human genes 0.000 description 2
- 102200048979 rs28929495 Human genes 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102100038776 ADP-ribosylation factor-related protein 1 Human genes 0.000 description 1
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102100035886 Adenine DNA glycosylase Human genes 0.000 description 1
- 102100024439 Adhesion G protein-coupled receptor A2 Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 102100021256 BCL-6 corepressor-like protein 1 Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 101100002344 Caenorhabditis elegans arid-1 gene Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100028003 Catenin alpha-1 Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102100025175 Cellular communication network factor 6 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 description 1
- 102100030977 Collagen alpha-3(IX) chain Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 1
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 1
- 102100029375 Crk-like protein Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000009503 Cyclin-Dependent Kinase Inhibitor p18 Human genes 0.000 description 1
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101150077031 DAXX gene Proteins 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 241000283715 Damaliscus lunatus Species 0.000 description 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 108091071901 ETS family Proteins 0.000 description 1
- 102000040848 ETS family Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 description 1
- 102100034553 Fanconi anemia group J protein Human genes 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100035292 Fibroblast growth factor 14 Human genes 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102100040859 Fizzy-related protein homolog Human genes 0.000 description 1
- 108010010285 Forkhead Box Protein L2 Proteins 0.000 description 1
- 102100035137 Forkhead box protein L2 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 102000017691 GABRA6 Human genes 0.000 description 1
- 102000017703 GABRG2 Human genes 0.000 description 1
- 102100027541 GTP-binding protein Rheb Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 102100036703 Guanine nucleotide-binding protein subunit alpha-13 Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 1
- 101000809413 Homo sapiens ADP-ribosylation factor-related protein 1 Proteins 0.000 description 1
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 description 1
- 101001000351 Homo sapiens Adenine DNA glycosylase Proteins 0.000 description 1
- 101000833358 Homo sapiens Adhesion G protein-coupled receptor A2 Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000894688 Homo sapiens BCL-6 corepressor-like protein 1 Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 1
- 101000934310 Homo sapiens Cellular communication network factor 6 Proteins 0.000 description 1
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 description 1
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101000878181 Homo sapiens Fibroblast growth factor 14 Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001001400 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-6 Proteins 0.000 description 1
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 description 1
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 description 1
- 101001072481 Homo sapiens Guanine nucleotide-binding protein subunit alpha-13 Proteins 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 description 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 1
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101001008854 Homo sapiens Kelch-like protein 6 Proteins 0.000 description 1
- 101001008857 Homo sapiens Kelch-like protein 7 Proteins 0.000 description 1
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 1
- 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 description 1
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 1
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000573451 Homo sapiens Msx2-interacting protein Proteins 0.000 description 1
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101001007909 Homo sapiens Nuclear pore complex protein Nup93 Proteins 0.000 description 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 1
- 101000945735 Homo sapiens Parafibromin Proteins 0.000 description 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 description 1
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 1
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 1
- 101000628776 Homo sapiens Protein mago nashi homolog Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000783404 Homo sapiens Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Proteins 0.000 description 1
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 description 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 description 1
- 101000666429 Homo sapiens Terminal nucleotidyltransferase 5C Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 description 1
- 101000723661 Homo sapiens Zinc finger protein 703 Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 1
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 102100027789 Kelch-like protein 7 Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 description 1
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 1
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 1
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102000017274 MDM4 Human genes 0.000 description 1
- 108050005300 MDM4 Proteins 0.000 description 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 102000046961 MRE11 Homologue Human genes 0.000 description 1
- 108700019589 MRE11 Homologue Proteins 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100026285 Msx2-interacting protein Human genes 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102100027585 Nuclear pore complex protein Nup93 Human genes 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 102100034743 Parafibromin Human genes 0.000 description 1
- 102100040884 Partner and localizer of BRCA2 Human genes 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100030128 Protein L-Myc Human genes 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 102100026740 Protein mago nashi homolog Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101150020518 RHEB gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 1
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 108700028341 SMARCB1 Proteins 0.000 description 1
- 101150008214 SMARCB1 gene Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100036122 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 101150045565 Socs1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 1
- 102100036422 Speckle-type POZ protein Human genes 0.000 description 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 description 1
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 1
- 102100026939 Suppressor of fused homolog Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 102100038305 Terminal nucleotidyltransferase 5C Human genes 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 description 1
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 102100036595 Zinc finger protein 217 Human genes 0.000 description 1
- 102100028376 Zinc finger protein 703 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000495 cryogel Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 101150071637 mre11 gene Proteins 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006485 reductive methylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/305—Fixative compositions
Definitions
- FFPE formalin fixation and paraffin embedding.
- FFPE is a highly efficient method that is currently the standard in pathology laboratories.
- Formalin-fixed, paraffin-embedded (FFPE) tissues may be stored indefinitely at room temperature, and nucleic acids (both DNA and RNA) may be recovered from them decades after fixation, making FFPE tissues an important resource for molecular assays.
- nucleic acids both DNA and RNA
- This disclosure relates to reagents and methods for preparing formalin-fixed, paraffin- embedded (FFPE) samples by combining test cells and / or tissues with a bulking agent having a physical differentiating feature from the test cells to provide a test mixture and preparing a FFPE sample therefrom.
- the bulking agent improves the visibility and / or uniformity of the test cells in the sample as compared to a sample prepared in the absence of the bulking agent, determined visually (e.g., able to be seen by the naked eye and differentiated from the test cells).
- the bulking agent comprises particles having a physical differentiating feature from the test cells.
- the particles are substantially the same size as the test cells and may be, for example, control cells.
- the physical differentiating feature may be, for instance, color which may, in some instances, be provided by a detectable label (e.g., fixably attached to the particles).
- the particles may not comprise a nucleus, DNA (e.g., nuclear DNA), and / or RNA (e.g., microRNA (miRNA), messenger RNA (mRNA)).
- the test cells comprise a genetic marker not detectable and / or not present in the bulking agent.
- the bulking agent consists essentially of control cells and / or may be and / or may comprise red blood cells (RBCs).
- this disclosure relates to formalin-fixed embedded quality control material for use in validation, verification, and as run controls for molecular assays.
- the quality control material can be used for a variety of tissues and for a variety of molecular assays.
- the quality control material can be used in commercial labs for validation or verification, including limit-of- detection analyses, precision analyses, and accuracy analyses.
- FIG. 1A shows an FFPE block manufactured with and without red blood cells.
- FIG. IB shows an FFPE block manufactured with red blood cells for processing DNA or RNA.
- FIG. 2 show FFPE sections in SafeClear during deparaffinization.
- This disclosure relates to reagents and methods for preparing formalin-fixed, paraffin- embedded (FFPE) samples by combining test cells and / or tissues with a bulking agent having a physical differentiating feature from the test cells to provide a test mixture and preparing a FFPE sample therefrom.
- FFPE formalin-fixed, paraffin- embedded
- Some embodiments described herein provide highly reproducible FFPE methods that provide for detection of one or more markers as described below.
- the use of the methods described herein with nucleic acid-based assays may allow for more efficient (e.g., simpler process, less time) isolation of nucleic acid (e.g., DNA, RNA) from the FFPE with an amount of degradation in the sample that mimics the in the assay.
- the samples prepared as described herein may serve as quality control material that may be used to validate, verify and / or provide controls for nucleic acid-based assays.
- quality control material may be used for a variety of tissues and in a variety of assay systems (e.g., including but not limited to limit-of-detection analyses, precision analyses, and accuracy analyses).
- the methods described herein provide highly reproducible FFPE methods that provide for detection of one or more markers.
- FFPE quality control FFPE product
- test cells containing at least one test marker in a background of bulking agent that comprises at least one physical differentiating feature from the test cells (e.g., particles such as cells (e.g., red blood cells (RBCs)).
- particles e.g., red blood cells (RBCs)
- RBCs red blood cells
- Laboratories performing FFPE-based molecular diagnostic tests typically use synthetic oligonucleotides, cell lines, genomic or plasmid DNA, or patient specimens as quality control material.
- synthetic material, cell lines, and genomic or plasmid DNA may not control for specific steps in the process.
- Patient specimens are often limited in quantity and inconsistent between sections, reducing the utility of the control material for monitoring trending over an extended period of time.
- a FFPE quality control material that mimics FFPE tissue and is homogenous and consistently produced lot-to-lot ensures that laboratories have access to a full process control that can be used over an indefinite period to monitor assay performance.
- the methods are highly reproducible within a lot and from lot-to-lot and provide for detection of one or more markers as described herein.
- the bulking agent may improve the visibility and / or uniformity of the test cells in the sample as compared to a sample prepared in the absence of the bulking agent.
- the "visibility" of a sample may be determined by any method available to those of ordinary skill in the art including, for example, visual inspection to identify and / or count cells within the sample and / or a particular area thereof. Visibility typically refers to able to be seen by the naked eye and differentiated from the test cells. Thus, visibility may be determined with respect to the number and / or type of cells and / or particles present within a particular area of the sample determined, for instance, visually, such that one type of cell and / or particle may be differentiated from another type (e.g., from test cells).
- Uniformity may be similarly determined with an emphasis on whether the test cells and / or particles are, for instance, sufficiently and / or substantially evenly spaced (e.g., distanced) from one another within the sample and/or if the cells in the FFPE section retain the shape expected from the mold (e.g., without noticeable distortion, other than shrinkage in size).
- a uniform sample may be one in which the test cells and / or particles are not present in "clumps" (e.g., areas of high cell and / or particle concentration) and / or where areas of the sample are devoid of test cells and / or particles. These determinations may be accomplished manually (e.g., using a microscope) or with the aid of an automated device to determine the number of cells present in each FFPE section.
- the bulking agent may comprise particles having one or more "physical differentiating features" from the test cells.
- a suitable physical differentiating feature may be, for instance, color, size and / or another detectable "marker".
- the physical differentiating feature may be, for instance, a difference in color that may, in some instances, be provided by the color (e.g., de novo) of the particle (e.g., encased colored particle, cell such as an RBC) and / or a detectable label (e.g., fixably attached to the particles).
- the bulking agent may comprise or be a colored substance.
- the colored substance could include dyes, pigments, or proteins.
- the particles may be of substantially different or substantially the same size as the test cells (e.g., another physical differentiating feature).
- the bulking agent may be any material that is between about any of 0.5 nm to 200 ⁇ in diameter, for instance.
- the test cells comprise one or more markers not detectable and / or not present in the bulking agent.
- the particles may also contain and / or lack a "genetic" marker (e.g., a "target sequence” such as a nucleic acid (DNA, RNA) and / or expressed protein) that is absent and / or present, respectively, in the test cells.
- a genetic marker may be "present” by either existing or being expressed within and / or by the particle (e.g., the genome, cytoplasm, or surface of a cell). Such a marker may be naturally present within the particle (e.g., a cell) or the particle may be manufactured to include the same.
- a particle e.g., a cell
- the particles may or may not comprise a nucleus, any or any particular type of DNA (e.g., nuclear DNA), and / or any particular type of RNA (e.g., microRNA (miRNA), messenger RNA (mRNA)) while the test cells conversely do or do not, respectively, comprise such components.
- the particle e.g., cell
- the bulking agent may consist essentially of particles that are control cells (e.g., mammalian cells) that express a physical differentiating feature from the test cells.
- Exemplary bulking agents, particles and / or cells include but are not limited to red blood cells, non-human cells such as bacterial, yeast, plant, or animal cells that have a color and / or do not contain the marker of interest.
- the bulking agent may be and / or comprise red blood cells (RBCs) where the test cells are mammalian cells (e.g., as described in the Examples section).
- RBCs red blood cells
- the physical differentiating feature may be color (e.g., where, unlike the RBCs the test cells are not red in color).
- Other suitable particles are also contemplated for use in these methods, as could be determined by one of ordinary skill in the art.
- the methods described herein may be used to solve problems associated with the preparation of FFPE material.
- a synthetic tissue typically includes the steps of obtaining a defined concentration of cellular material; mixing the cellular material with a gelling polymer to create a gel/cellular material; adding the gel/cellular material to a mold (e.g., a polypropylene cylinder) with a defined shape until the gelling polymer solidifies; and, slicing the solidified material to a uniform and defined size.
- the methods also include formalin fixing the sliced solidified material.
- the methods also include embedding the material in paraffin.
- the cellular material includes test cells and one or more bulking agents.
- the cellular material comprises a known number of test cells and one or more bulking agents (e.g., a known amount) in a homogeneous mixture.
- the test cells may comprise at least one marker to be detected that is not present in the bulking agent (e.g., one or more DNA and / or RNA sequences).
- the sample may comprise both test cells and bulking agent (e.g., particles, cells, RBCs) in known amounts of one or both of the test cells (e.g, optionally including background and / or control cells) and the bulking agent.
- the mixture of test cells and bulking agent e.g., particles, RBCs
- the mixture of test cells and bulking agent consists of about 10 ⁇ 12 to about 100,000% bulking agent (e.g., in some embodiments, the lower limit may be about one bulking agent (e.g., particle) per 10 10 test cells and the upper limit may be about one thousand bulking agents per test cell).
- the mixture to be fixed may comprise about 10 "12 to about 100,000% test cells (e.g., 10 "12 , 10 ⁇ n , 10 "10 , 10 “9 , 10 “8 , 10 “7 , 10 “6 , 10 “5 , 10 “ 4 , .001, 0.005, 0.006, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,
- test cells
- a defined concentration of test cells is admixed with a defined concentration of bulking agent (e.g., particles such as cells), admixed with a gelling polymer, and formalin-fixed.
- This process also typically involves dehydration, clearing and infiltration steps.
- the synthetic tissue may shrink in size or become otherwise deformed, resulting in a sample that is difficult to further process.
- the shrinkage of a synthetic tissue with a low cell concentration e.g., approximately 1 x 10 7 cells/mL or less including but not limited to any of approximately 10 6 , 10 5 , 10 4 , 10 3 , 10 2 or 10 cells/ml
- a low cell concentration e.g., approximately 1 x 10 7 cells/mL or less including but not limited to any of approximately 10 6 , 10 5 , 10 4 , 10 3 , 10 2 or 10 cells/ml
- a bulking agent (RBCs) was added to the cellular material containing the target for the diagnostic assay system and observed to reduce shrinkage and improve uniformity.
- RBCs were selected because these may be processed similarly to test cells, but do not contain a nucleus and therefore do not contain nuclear DNA. Accordingly, the marker of interest (e.g., target of interest, the KRAS sequence in the Examples) is not present in the RBCs. In this way, the bulking agent was used to increase the total cell concentration of the sample for processing without diluting the target of interest.
- the sample may comprise test cells (e.g., a defined concentration of test cells) admixed with the bulking agent (e.g., a defined concentration of particles (e.g., cells such as RBCs)), where the test cells comprise one or more markers (e.g., color, size, nucleic acid-, protein-, carbohydrate-, and / or lipid-based marker) and the bulking agent does not comprise the one or more markers. That marker is typically considered a differentiating feature or, more specifically, a physical differentiating feature.
- the test cells may be cancer cells.
- the test cells are a mixture of cancer cells and non-cancer cells.
- the test cells are non- cancer cells.
- the test cells may be derived from a biopsy.
- the sample may comprise, for instance, cells having and / or expressing a genetic marker (e.g., a target sequence) of cancer such as a SNP (single nucleotide polymorphism), insertion, deletion, translocation, fusion, CNV (copy number variation) etc, and cells lacking and / or not expressing that genetic marker (e.g., a cell line containing the wild-type allele).
- a genetic marker e.g., a target sequence
- the cell mixtures may be mixed with a suitable excipient (e.g., agarose) and a bulking agent (e.g., RBCs) and aliquoted into a suitable mold (e.g., a polypropylene cylindrical mold).
- a suitable excipient e.g., agarose
- a bulking agent e.g., RBCs
- the cell- excipient mixture may then be allowed to solidify (e.g., in the form of a cylinder), the resultant product removed therefrom, and placed on a sterile surface.
- a slicing apparatus may then be used to slice the cylinder into equal parts. Each part may then be formalin fixed and embedded according to standard procedures (e.g., as in the Examples herein).
- a microtome may be used to slice the FFPE blocks into sections of defined thickness that may be placed into vials or onto microscope slides.
- the resulting FFPE slice can be referred to as the quality control (QC) sample.
- QC quality control
- each of the above-described steps may or may not be distinct steps (e.g., one or more steps may be combined), may or may not include additional steps not listed, and / or may also comprise less than all of these steps.
- FFPE specimens require processing steps prior to analysis. These steps can include, without limitation: deparaffinization, reversal of cross linking, extraction, nucleic acid yield test, and amplification/detection. These may be accomplished using any suitable techniques, which are well known to those of ordinary skill in the art.
- the genetic marker may relate to any one or more of the cells lines, mutations and / or genes listed in Tables 1 and 2. These are non-limiting examples of genetic markers. One of skill in the art will appreciate that any genetic marker can be incorporated into the compositions and methods disclosed herein.
- ARID 1 A ERBB4 KDM5C PPP2R1A
- CDK6 GID4 (C17orf39) MYCN STK11
- CDKN2A GNAQ NF1 TGFBR2
- suitable markers may include, for instance, allele- specific and / or cell type-specific biomarkers.
- biomarkers for tumor cells of epithelial origins may include, for instance, one or more of cytokeratin, EPCAM, ICAM, etc., or cancer related markers, including CEA (carcinoembryonic antigen).
- prostate cancer cells usually express prostate-specific antigen (PSA).
- Allelic variants may include, by way of non-limiting example, BRAF- 1799TA, CTNNB 1-121 AG, CTNNB1-134CT, EGFR-2369CT, EGFR-2573TG, KRAS- 34GA, KRAS-35GA, KRAS-38GA, KRAS-176CG, KRAS-183AC, NRAS-35GA, NRAS- 38GA, NRAS-181CA, NRAS- 183 AT, TP53-524GA, TP53-637CT, TP53-721TG, TP53- 733GA, TP53-742CT, TP53-743GA, TP53-817CT, and the like as described in, for example, US 2010/0221717 Al (U.S. Ser.
- allele refers generally to alternative DNA sequences at the same physical locus on a segment of DNA, such as, for example, on homologous chromosomes.
- An allele can refer to DNA sequences which differ between the same physical locus found on homologous chromosomes within a single cell or organism or which differ at the same physical locus in multiple cells or organisms ("allelic variant").
- an allele can correspond to a single nucleotide difference at a particular physical locus.
- allele can correspond to nucleotide (single or multiple) insertion or deletion. These markers are normally not found or expressed (or expressed in much lower level) in normal circulating blood cells (e.g., the exemplary bulking agent RBCs).
- any one or more of these cells lines and / or markers may be used alone and / or in combination with one another.
- Multiplex molecular assays allow for the detection of multiple test cells. Therefore, further embodiments include the step of pooling samples to be tested prior to using the multiplexed assays described herein.
- different slices with individual mutations can be placed together in 1 tube (to be processed together).
- 1 slice from the G12V and 1 slice from the G12D mutations could be placed together to make a multiplex control (e.g., Table 7).
- Other markers may also be suitable as would be understood by those of ordinary skill in the art and any number of markers can be combined to produce a multiplex control.
- the marker may be any marker known in the art and can be used to perform cancer research, diagnose disease, prognosticate disease and/or to test disease for drug effectiveness.
- the sample (e.g., cell material) and / or bulking agent to be processed by the methods described herein may be obtained from any cell, tissue or organ of any type of organism.
- the cell material may include one or more prokaryotic cells and / or one or more eukaryotic cells including but not limited to a protozoa, fungus, plant, animal (e.g., human).
- the cells may be, for instance, hematopoietic cells.
- the cells may be cancer cells and / or infected cells.
- the cells may be tissue culture cells.
- the cells may also be obtained from a biopsy. In some embodiments, a tissue sample is disrupted into cells to prepare a homogeneous material for FFPE processing.
- the sample e.g., cell material
- the test cells may be cells that contain and / or express and / or are considered "positive" for one or more particular marker or markers that are not present in the bulking agent (e.g., particles (e.g., cells)).
- the cell material may contain more than one type of test cell. For example, if two different markers are diagnostic for a particular disease, two different test cells may be included, with one test cell being positive for one marker and the other test cell being positive for a second marker.
- the sample may also contain a bulking agent.
- the cell material can contain background cells (e.g., cells that do not contain the marker and/or contains a wild-type marker instead).
- the background cells may make up between, for example, about 1 to about 99.9% (e.g., about any of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97.5, 99, 99.5 or 99.9%) of the cells in the sample.
- the background cells may be fixed or unfixed along with or when added to the test cell and / or bulking agent mixture.
- the test cells and bulking agent may be mixed and then fixed to form a mixture for processing.
- the test cells may be fixed and then mixed with the one or more bulking agents for preparation of FFPE blocks.
- the test cells may be fixed and the bulking agent may be fixed or unfixed in the mixture.
- the test cell and bulking agent can be mixed before fixation.
- the test cell and the bulking agent can be mixed after the cells are fixed.
- the cell material is a formalin fixed (or other fixed) sample and/or an FFPE sample of tissue. In this case, because it would be difficult or impossible to disrupt the FFPE tissue into separate cells, the cell material can be used for a positive or negative control.
- the cells are unfixed, they may be frozen.
- cells can be mixed with polymer, solidified and then frozen. When this technique is used, an agent, such as glycerol may be added to the polymer to prevent cracking.
- the bulking material can be synthetic. Any suitable synthethic particles can be used. Nonlimiting examples include: 3000 Series NANOSPERE size standards, 4000 Series Monosized particles, 3K/4K Series Particle Counter Standards, 4D Seried Dry Microsphere Size Standards, and 8000 Series Silica Particle Size Standards (Thermo Fisher Scientific).
- the excipient or excipients used to create the solidified mixture of test cells and bulking agent may comprise a gel (e.g., any colloidal suspension of a solid dispersed in a liquid).
- a suitable excipient may be any gel that may be mixed with test cells without changing the properties of the test cells such that the parameter being tested (e.g., the presence and / or expression and / or character of a particular nucleic acid, protein, carbohydrate and / or lipid) cannot be, or is at least less efficiently or more difficult to assay.
- a suitable gel may be any gel that can change from a liquid or semi-solid state (suitable for mixing with test cells) to a solid or gelled state (e.g., such that it may be sliced).
- the gel may be an agarose, agar, carageenan, pectin, egg yolk, any type of polymer, and / or mixtures thereof.
- the gel is a polymer that may be solidified or hardened (e.g., using a cross-linking agent, motion and / or temperature). Solidified or hardened refers to the ability of a gel to be converted from a liquid or semi- liquid state to a solid or semi-solid state.
- Temperature- solidified gels may also be suitable. Most suitable of these types of gels are those that do not require an amount of heat to that would be detrimental to the test cells and / or the bulking agent(s).
- suitable gels may or may not contain inhibitory substances.
- the gel does not contain an inhibitory substance that may inhibit the fixation, embedding, or downstream molecular tests.
- a pre-defined concentration of inhibitor could be added such as typically found in a human specimen. For example, heme molecules from red blood cells can inhibit PCR. A gel containing heme molecules therefore could serve as a control for extraction step efficiency in an assay if the concentration therein in comparable to a normal human sample.
- Other excipients are also contemplated as would be understood by those of ordinary skill in the art.
- the mold can be any shape known to the skilled artisan that allow for slicing.
- the shape of the mold can be a cylinder.
- the cylinder can be of any length and diameter such that a useful sized slice is produced.
- the cylinder can be made of any material that will keep its shape when a hot gel is poured into it.
- the material will not stick to the gel/cellular material mixture.
- the material will not affect the cellular integrity.
- the material can be removed from the solidified gel/cellular material mixture. In some embodiments, the material can be removed without sticking to the gel/cellular material mixture.
- the ends of the cylindrical material can be cut off and the tube of hardened gel/cellular material can be slid out.
- Materials may include, for instance, polypropylene and equivalent plastic materials. Other materials can be envisioned that might require producing a mold that can be opened and closed, for example glass, metals, and very hard plastics.
- the cylindrical solidified gel/cellular material can then be sliced into sections of a uniform and defined size. This ensures that the amount of nucleic acid in each slice will be equivalent.
- the cylindrical solidified gel/cellular material mixture may be sliced using any method known in the art that results in slices of uniform and defined sizes.
- the slicer may be a modified egg slicer, modified so that the base is removed and the tines (e.g., which are equidistant from each other) are more easily usable. Any slicer with equidistant slicing ability could be used.
- the slicing wires or blades are spaced 1 mm to 5 mm apart.
- other methods of providing for equivalent samples e.g., slices
- Any tool can be used that provides a sample with a constant volume. Exemplary methods include using a tool to obtain a plug, or using a syringe to obtain an even amount of liquefied sample (e.g., liquefied gel/cellular material).
- Chemical fixatives are used to preserve tissue from degradation, and to maintain the structure of the cell and of sub-cellular components such as cell organelles (e.g., nucleus, endoplasmic reticulum, mitochondria) and may be used in the methods described herein.
- the most common fixative for FFPE is neutral buffered formalin (4% formaldehyde in phosphate buffered saline).
- Fixatives preserve tissues or cells mainly by irreversibly cross-linking proteins.
- the main action of these aldehyde fixatives is to cross-link amino groups in proteins through the formation of CH 2 (methylene) linkage, in the case of formaldehyde, or by a C5H1 0 cross-links in the case of glutaraldehyde.
- the sliced solidified gel/cellular material may be immersed in a fixative, such as a solution with a protein crosslinking activity, such as but not limited to a formaldehyde solution, glutaraldehyde solution, formaldehyde-alcohol mixed solution, alcohol solution, Bouin's solution, Zenker solution, Hely solution, osmic acid solution, Carnoy solution, standard saline citrate (SSC) and RNAeasyTM, and equivalents thereof.
- the fixative is formalin.
- the formaldehyde can be in any kind of buffer.
- fixative alcohols include thanol and isopropanol. These fixatives are commercially available.
- the time of fixation may be from any of about 0.5 to about 72 hours, including but not limited to about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, and 71 hours.
- the temperature of fixation can be from about 4°C to about 26°C, including but not limited to, any of about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25°C. Other conditions for fixation are also contemplated as would be understood by those of ordinary skill in the art.
- an embedding step may be carried out.
- the tissue samples are placed into molds along with liquid embedding material (such as agar, gelatin, or wax) which is then hardened. This is achieved by cooling in the case of paraffin wax and heating (curing) in the case of the epoxy resins.
- the acrylic resins are polymerized by heat, ultraviolet light, or chemical catalysts.
- the hardened blocks containing the tissue samples are then ready to be sectioned. Because formalin-fixed, paraffin- embedded (FFPE) tissues may be stored indefinitely at room temperature, and nucleic acids (both DNA and RNA) may be recovered from them decades after fixation, this makes FFPE tissues an important resource for historical studies in medicine.
- Embedding can also be accomplished using frozen, non-fixed tissue in a water-based medium.
- Pre-frozen tissues are placed into molds with the liquid embedding material, usually a water-based glycol, OCT, TBS, Cryogel, or resin, which is then frozen to form hardened blocks.
- the resulting blocks can be sectioned using methods known in the art, including, but not limited to, microtomes, vibratory microtomes and cryostats and the like.
- An exemplary method comprises:
- Sections may be deparaffinized using methods known in the art and/or commercially available kits.
- the methods remove the bulk of paraffin from the sample.
- Various techniques are known for deparaffinizing and include, but are not limited to, washing with an organic solvent or agent to dissolve the paraffin.
- Solvents may include but are not limited to, benzene, toluene, ethylbenzene, xylenes, D-li-monene, octane, and mixtures thereof. These solvents are preferably of high purity, usually greater than 99%. The volume used and the number of washes necessary will depend on the size of the sample and the amount of paraffin to be removed.
- a sample may be washed between 1 and about 10 times, or between about two and about four times.
- a typical volume of organic solvent is about 500 ml for a 10 mm tissue sample.
- samples are preferably wash such as by step-wise washing with aqueous lower alcoholic solutions of decreasing concentrations.
- Ethanol is a preferred lower alcohol for wash while other alcohols may also be used.
- Non-limiting examples include methanol, isopropanol, and other C1-C5 alcohols.
- the sample is alternatively vigorously mixed with alcoholic solutions followed by its removal. In one embodiment, the concentration of alcohol is stepwise lowered.
- the sections may be used to isolate DNA or RNA for identification of the presence of a marker and/or for expression of a marker using standard techniques.
- the markers can be used for investigational purposes, diagnosis, prognosis, typing, and/or staging of disease.
- the marker(s) may include DNA or RNA (e.g., for the presence and / or expression levels thereof in test cells).
- Exemplary markers include, for instance, the genes (or proteins expressed therefrom) listed in Table 2.
- thymidylate synthase is an integral enzyme in DNA biosynthesis where it catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) and provides the only route for de novo synthesis of pyrimidine nucleotides within the cell (Johnston et al., 2002, J. Clinical Oncology, 20(7) pp. 1721-1728).
- Thymidylate synthase is a target for chemotherapeutic drugs, most commonly the antifolate agent 5-fluorouracil (5-FU).
- 5- FU As the most effective single agent for the treatment of colon, head and neck and breast cancers, the primary action of 5- FU is to inhibit TS activity, resulting in depletion of intracellular thymine levels and subsequently leading to cell death.
- Other markers that can be tested for include, but are not limited to: HIPl in the diagnosis and treatment of lymphoma and brain cancers; TS and/or ERCC1 expression levels prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies; recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer; ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
- Hematopoietic cancers or metastases may also be tested using the reagents and methods described herein (e.g., QC FFPE controls).
- Cancers which involve cells generated during hematopoiesis a process by which cellular elements of blood, such as lymphocytes, leukocytes, platelets, erythrocytes and natural killer cells are generated are referred to as hematopoietic cancers.
- Lymphocytes which can be found in blood and lymphatic tissue and are critical for immune response are categorized into two main classes of lymphocytes: B lymphocytes (B cells) and T lymphocytes (T cells), which mediate humoral and cell mediated immunity, respectively.
- B cells B lymphocytes
- T lymphocytes T lymphocytes
- Many of these cancers are characterized by recurrent translocations that can be detected from FFPE using methods discussed herein.
- Exemplary DNA molecules may include, for instance, genomic DNA, mitochondrial DNA, cDNA or other DNA.
- Exemplary RNAs that may be detected may include, for example, messenger RNA (mRNA), non-coding RNA (including long non- coding RNA), antisense RNA, CRISPR RNA, microRNA, small-interfering RNA (siRNA), pathogen-associated RNAs (e.g., bacterial or viral RNAs), and the like.
- mRNA messenger RNA
- non-coding RNA including long non- coding RNA
- antisense RNA CRISPR RNA
- microRNA microRNA
- siRNA small-interfering RNA
- pathogen-associated RNAs e.g., bacterial or viral RNAs
- Such RNA molecules may be detected using any of the available methods of detection including, for example, next generation sequencing (NGS), RT-PCR, microarray-based systems, and the like.
- NGS next generation sequencing
- RT-PCR RT-PCR
- a combination of cell lines can be detected.
- a plurality of cell lines can be utilized in equal or unequal proportion.
- a plurality (i.e., 2 or more) of cell lines can be combined in equal proportion wherein each contains a different fusion mRNA gene, thereby providing an FFPE fusion control material.
- kits comprising one or more reagents for carrying out the methods described herein along with, optionally, instructions for use.
- a "kit,” as used herein, may refer to a combination of at least one QC sample for FFPE prepared using the methods described herein (e.g., a FFPE slice of a gelled homogeneous mixture of test cells and bulking agent (e.g., RBCs)).
- kits may be used to prepare samples for FFPE.
- At least one quality control sample (e.g., including at least one type of test cell comprising a marker and at least one bulking agent comprising a physical differentiating feature) for FFPE may be made by the methods described herein and included in a kit.
- the kit may also include multiple samples containing different types of test cells.
- the kit may contain a combination of QC samples organized in such a way as to provide controls for all variations of a particular marker.
- the variations of the marker are variations of an oncogene that is diagnostic for a particular cancer (e.g., see Tables 1 and 2).
- the variations of the marker are variations of a mutation in a gene that are prognostic for the usefulness of treating with a drug.
- the kit includes a number of different markers that are diagnostic of a particular cancer.
- the marker or markers are for a particular disease.
- the marker or markers are for a variety of diseases.
- the marker or markers test for drug efficacy for a disease.
- the marker or markers test for diagnosis of a disease or a group of related diseases. In some embodiments, the marker or markers test for a series of diseases that have common characteristics and/or symptoms. In some embodiments, for instance, the kit may comprise samples known to cover the breadth of mutations known for a particular cancer. In some embodiments, the marker may have unknown significance but may otherwise be of interest to the user (e.g., for basic research purposes). Other types of kits are also contemplated herein as would be understood by those of ordinary skill in the art.
- the kit may also include a container (e.g., vial, test tube, flask, bottle, syringe or other packaging system (e.g., include injection or blow-molded plastic containers) into which a reagent may be placed / contained, and in some embodiments, aliquoted) for containing any one or more reagents of the kit.
- a container e.g., vial, test tube, flask, bottle, syringe or other packaging system (e.g., include injection or blow-molded plastic containers) into which a reagent may be placed / contained, and in some embodiments, aliquoted) for containing any one or more reagents of the kit.
- a container e.g., vial, test tube, flask, bottle, syringe or other packaging system (e.g., include injection or blow-molded plastic containers) into which a reagent may be placed / contained, and in some embodiments, aliquoted) for containing any one
- the liquid solution comprises an aqueous solution that can be a sterile aqueous solution.
- a kit can also include instructions for employing the kit components as well as the use of any other reagent not included in the kit. Instructions may include variations that can be implemented. The instructions may be provided as a separate part of the kit (e.g., a paper or plastic insert or attachment) or as an internet-based application. In some embodiments, the kit may contain QC FFPE samples for between any of about 1 to 1000 markers which may be detected alone or in combination with one another (e.g., a multiplex assay).
- the kit may also comprise at least one other sample containing a defined concentration of a test cell admixed with the bulking agent at the concentrations described herein or otherwise found to be suitable.
- the kit may include QC FFPE samples of various test cells to bulking agent ratios as described above.
- the kit may alternatively or also include, for instance, QC FFPE slices containing bulking agent and mixtures of wild-type to mutant test cells in concentrations of about 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%.
- Exemplary kits are provided in Examples 3 and 4 herein. Other variations and arrangements for the kits of this disclosure are contemplated as would be understood by those of ordinary skill in the art.
- FFPE formalin fixed paraffin embedded
- QC quality control
- the terms “marker” and “test marker” may be interchangeable and may refer to a cellular component specific to a particular disease, whether of unknown significance, prognostic, diagnostic, and/or with reference to treatment.
- the marker may be a DNA, RNA, protein, carbohydrate and / or lipid marker.
- the marker may relate to any type of mutation associated with a disease. Markers may be associated with but are not limited to, translocations, alleles, single nucleotide polymorphisms (SNPs), expression profiles, etc. Such markers may relate to any type of nucleic acid including but not limited to DNA and / or RNA (mRNA, rRNA, tRNA, mitochondrial RNA).
- the markers may relate to genes, SNPs, microsatellites, translocations, alleles, mutations (e.g., multiple nucleotide and/or large deletions, additions, or changes), multi-RNA complexes, splice variants, transposons, ribozymes, microRNAs (primary, pre- or mature microRNAs), bacterial genomes, plasmids, viral genomes, and / or viroids.
- a DNA-based marker may be used to identify the presence of a SNP.
- a RNA-based marker may be used to identify the expression of a SNP.
- gelling polymer or “gel” are interchangeable and may refer to a colloidal suspension of a solid dispersed in a liquid (e.g., a semi-rigid solid).
- homogeneous may refer to a mixture that exhibits uniformity.
- the components may be intermixed in a uniform manner such that each portion (e.g., slice) contains approximately the same concentration of test cells and bulking agent as substantially any other portions (e.g., slices).
- exemplary test cells may include but are not limited to, cancer cells, cells from a patient, cells from a biopsy, hematopoietic cells, tissue culture cells, and / or cells of a tissue.
- background cell may be interchangeable and refer to a cell that does not contain the marker that is being tested for. In some cases, such a cell may be a wild-type cell of the same type as the test cell.
- patient may refer to any human or animal that is tested and/or treated for disease.
- the term “mold” may refer to a hollow cavity form or matrix into which a liquid or semi-liquid material is placed to take a desired shape upon cooling or drying.
- test cell may refer to a cell that is being tested to determine whether it contains one or more particular markers.
- cylindrical refers to something having the shape of a cylinder, an object shaped like a tube, an object or shape (e.g., rectangle, square, triangular cylinder) with straight sides and circular ends of equal size.
- solidified and “hardened” may be used interchangeably and, with respect to a gel, refer to the ability of a gel to go from a liquid or semi-liquid state to a solid or semi-solid state.
- a polymer may be introduced into a cylindrical tube in a fluid form, then allowed to gel to a solid form by cooling.
- Gels may also be solidified by adding a cross-linker, by motion, and/or by other methods known to those of skill in the art.
- a cross-linker By motion, and/or by other methods known to those of skill in the art.
- the term "fix” may refer to a method of preserving cells or tissue, which may include the irreversible cross-linking of proteins on and / or within cells.
- range is meant to include the starting value and the ending value and any value or value range therebetween unless otherwise specifically stated.
- “from 0.2 to 0.5” may mean 0.2, 0.3, 0.4, and 0.5; ranges therebetween such as 0.2-0.3, 0.3 - 0.4, 0.2 - 0.4; increments there between such as 0.25, 0.35, 0.225, 0.335, 0.49; increment ranges there between such as 0.26 - 0.39; and the like.
- the term “about” or “approximately” may refer the ordinary meaning of the term but may also indicate a value or values within about any of 1-10 percent of the listed value.
- Tables 3-5 provide materials, consumable and instruments used in the following examples.
- the examples use the KRAS molecular markers to demonstrate the usefulness of the quality control FFPE methods.
- Seven mutations (G12D, G12V, G12C, G12S, G12A, G12R, G13D) comprise 98.5% of known KRAS mutations that are involved in identifying the usefulness of chemotherapy on colorectal cancers.
- a cell line containing the KRAS G12C mutation was obtained and mixed with red blood cells as described in Example 1.
- the method using an exemplary bulking agent (RBCs) was compared to the method carried out without a bulking agent, as described below.
- the method including RBCs was found to promote uniformity of the cell-containing polymer (referred to as the synthetic tissue) during the FFPE process. This improves the ease of manufacturing FFPE controls and increases the yield of the number of sections per block due to the increased size.
- the method including RBCs also improved the ease of extraction because the cell pellet was easier to see in the tube after deparaffinization.
- This example demonstrates the feasibility of manufacturing qualitative formalin-fixed paraffin embedded (FFPE) KRAS Positive Control products using the method herein with red blood cells.
- the study demonstrates the ability to manufacture and value assign stock materials from sourced raw materials, the reproducibility of the product, detection of the product on target assays, as well as comparison of the products' DNA quality to those of the old FFPE method.
- the cell line having the KRAS G12C mutation SW1463 was obtained from ATCC (Manassas, VA) and grown to a total of 1.0 x 10 9 cells.
- Stock materials are manufactured in Cell Freezing Media and were value- as signed against a calibrator (quantified by counting with a hemacytometer) using the Roche Light CyclerTM Control Beta-Globin test.
- An incubator was set to 45°C. 1 % agarose was prepared and allowed to come to 45°C in the incubator. Human red blood cells (RBCs) were spun down in a microcentrifuge at maximum speed. The RBC's were washed with DMEM and the wash was repeated until the lysed cells were removed. The cells were spun down and 4g of RBC's were mixed with 6 mL of DMEM. An appropriate amount of cells containing the KRAS G12C mutation was measured gravimetrically into a sterile cup. The cells were mixed with wild-type cells (that do not contain the KRAS G12C mutation) with a mutant cell percentage of 10%.
- Two (2) mL of fixed cells containing the KRAS G12C (test cells plus wild-type cells) were mixed with 3 mL of a RBC mixture (0.4 g of RBC cells per mL of DMEM).
- the cellular mixture was warmed for 20 min. to 45°C.
- 0.5 mL of the agarose (at 45°C) was mixed with the cellular mixture (the fixed cells and RBCs) and poured into a tissue mold.
- the tissue mold was placed at -20°C for 7 minutes to quickly solidify the agarose/cellular mixture.
- the tissue mold was then placed in a refrigerator at 2-8 °C overnight.
- the cylinder was cut into minicylinders and processed following the FFPE manufacturing procedure (the 70% alcohol step was performed for 1 nr.) then embedded.
- the fixed mini-cylinders were transferred into labeled tissue cassettes.
- the tissue cassettes were transferred into a container filled with 70% alcohol and incubated for a minimum of 1 hour.
- the alcohol was decanted and excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely.
- the tissue cassettes were then transferred into a container filled with 95% alcohol and incubated for 1 hour.
- the alcohol was decanted and excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely.
- the tissue cassettes were then transferred into a container filled with 100% alcohol and incubated for 1 hour.
- the alcohol was decanted and the excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely.
- the tissue cassettes were transferred into a container filled with SafeclearTM and incubated for 30 minutes.
- the SafeclearTM was decanted and excess removed using absorbent paper.
- the tissue cassettes were not allowed to dry completely.
- the tissue cassettes were transferred into a container filled with a 1 : 1 mixture of SafeclearTM and melted paraffin and incubated for 30 minutes at 65 °C.
- the 1 : 1 mixture of SafeclearTM and melted paraffin was decanted into a waste container.
- the tissue cassettes were transferred into container filled with melted paraffin and incubated for 1 hour at 65°C.
- the melted paraffin was decanted into a waste container.
- the tissue cassettes were then transferred into a container filled with melted paraffin and incubated for 2 hours at 65 °C.
- the fixed mini-cylinders were then transferred into a tissue mold containing melted paraffin.
- the base of the tissue cassette was placed over the tissue mold and paraffin was dispensed from the paraffin-embedding instrument until the mold and cassette were filled.
- the filled tissue mold was placed onto the refrigerated unit of the paraffin-embedder and allowed to harden for at least 1 hour.
- the FFPE blocks were sectioned on a Microtome into the appropriate thickness. The section was transferred using forceps into a sterile tube.
- FIGS. 1 and 2 show that the sections with the red blood cells retained the cylindrical shape and were easier to see as compared to the sections that did not contain the red blood cells.
- the block was manufactured without red blood cells, while the block on in FIG. IB was manufactured at the same concentration using red blood cells.
- FIG. IB shows that during the process of FFPE (and/or DNA or RNA extraction), inclusion of the exemplary bulking agent (RBCs) made it easier to see the cell-containing portion of the block.
- FIG. 2 shows the section without red blood cells on the left and the section without red blood cells on the right during deparaffinization. SafeClear was added to the sections for deparaffinization. The section including the exemplary bulking agent (RBCs) was found to be easier to see, making the extraction process easier for users.
- CT MT Mean Mutant CT
- CT is an abbreviation for cycle threshold, which describes the cycle number in qPCR when the fluorescence crosses a defined threshold (see, e.g., U.S. Patent Nos. 6,303,305; 6,503,720; 6,783,934, 7,228,237 and U.S. Application No. 2004/0096819).
- cycle threshold describes the cycle number in qPCR when the fluorescence crosses a defined threshold.
- By comparing the mutant CT value and wild- type CT value it is possible to compare the relative level of mutant vs. wild-type and calculate the mutant % of the sample. As shown in Table 6, the mutant percentage (see right most column) was very similar for both the new (Example 1A) and prior methods (Example IB).
- Each column in Table 6 represents a step for calculating the mutant %.
- this data shows that the inclusion of an exemplary bulking agent (RBCs) did not affect the quality of the DNA in the sample as shown using PCR.
- a KRAS FFPE kit is prepared containing controls intended for use in assessing the performance of nucleic acid test procedures for the determination of KRAS mutations using the methods in Examples 1 and 2 (see Table 6; 1 vial per KRAS mutation and 1 wildtype (negative control)). Routine use of the KRAS FFPE controls enables laboratories to monitor day-to-day assay variation, lot-to-lot performance of assay reagents, and operator variation. The KRAS FFPE controls can also assist in identifying increases in random or systematic error in testing systems.
- the KRAS FFPE Controls kit contains controls for the seven major KRAS mutations and a wild type control.
- Each individual control consists of KRAS mutation-positive cells mixed with the RBC bulking agent that has been formalin-fixed and paraffin-embedded and sectioned to 10 microns thick.
- the KRAS FFPE Controls are designed to meet the need for controls for molecular testing of KRAS in FFPE samples. The independent set of external controls helps to ensure that KRAS nucleic acid testing procedures are consistent across manufacturers, testing laboratories, operators, platforms and assay formats.
- the KRAS FFPE Controls are formulated to mimic formalin fixed paraffin embedded tissues and designed to monitor all procedural steps in extracting human DNA from FFPE. The intact human cells allow for the verification of effective DNA extraction and purification.
- KRAS test methodology includes an extraction step that releases the DNA for amplification and detection, as appropriate to the test.
- An EGFR FFPE kit is prepared containing controls intended for use in assessing the performance of nucleic acid test procedures for the determination of EGFR mutations using the methods in Examples 1 and 2. Routine use of the EGFR FFPE controls enables laboratories to monitor day-to-day assay variation, lot-to-lot performance of assay reagents, and operator variation. The EGFR FFPE controls also assist in identifying increases in random or systematic error in testing systems.
- the EGFR FFPE Controls kit contains controls for 29 major EGFR mutations that are associated with drug resistance to chemotherapy drugs and a wild type sequence (see Table 7 for mutations).
- Each individual control consists of EGFR mutation-positive cells admixed with red blood cells and formalin- fixed and paraffin-embedded and sectioned to 10 microns thick.
- An EGFR wildtype cell control can be included also.
- the EGFR FFPE Control meets the need for controls for molecular testing of EGFR in FFPE samples.
- the kit contains 29 slices containing mixtures of EGFR mutations in a background of red blood cells and 1 slice containing an EGFR wildtype cell in a background of red blood cells.
- the independent set of external controls helps to ensure that EGFR nucleic acid testing procedures are consistent across manufacturers, testing laboratories, operators, platforms and assay formats.
- the EGFR FFPE Controls are formulated to mimic formalin fixed paraffin embedded tissues and are designed to monitor all procedural steps in extracting human DNA from FFPE.
- the intact human cells allow for the verification of effective DNA extraction and purification.
- EGFR test methodology includes an extraction step that releases the DNA for amplification and detection, as appropriate to the test.
- a procedure for manufacturing FFPE Blocks is described in this example.
- a sterile cup is filled to the 80ml line with 10% Neutral Buffered Formalin and swirled until all mini- cylinders (the slices) have separated.
- the mini-cylinders are placed in 10% Neutral Buffered Formalin for 2 hours at room temperature in the shaker set at 125 RPM, labeled and lidded.
- the 10% Neutral Buffered Formalin is decanted into the appropriate waste container and the mini-cylinders poured into a sterile Petri dish base.
- the tissue cassette is placed onto the sterile lid of the Petri dish and mini-cylinders transferred into tissue cassettes. A maximum of the same four mini-cylinders could be placed into one tissue cassette.
- the lid is closed and tissue cassettes placed into an appropriate container with 70% Alcohol.
- the volume of the 70% Alcohol reached above the tissue cassettes.
- a minimum fill at the 80ml line of the disposable sterile cup is required. It is incubated for a minimum of 1 hour with a maximum of 24 hours. For a hold time of 1 hour, it is incubated at room temperature. Any hold times that exceeded one hour would be incubated at 2-8°C.
- 70% Alcohol is decanted into a dedicated waste container.
- the Container is inverted and tissue cassettes are poured over an absorbent paper. The tissue cassettes are transferred into an appropriately- sized container with 95% Ethanol (ensure that the volume of the 95% Ethanol reaches above the tissue cassette).
- a minimum of approximately 80mL of 95% Ethanol is required. It is incubated for 55 to 65 minutes at room temperature.
- the Paraffin Embedder Instrument is turned on. An appropriate amount of paraffin is in each reservoir.
- the incubator/shaker is turned on and temperature set at 65°C. Clean sterile Polypropylene containers are filled with Paraffin until it reaches the top opening and placed in an incubator shaking at 125 RPM. 95% Alcohol was decanted into an appropriate waste container.
- the container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry).
- the tissue cassettes are transferred into an appropriately sized container with 100% Ethanol (ensuring that the volume of the 100% Ethanol reaches above the tissue cassette) and incubated between 60 to 80 minutes at Room Temperature. A minimum of approximately 80mL of 100% Ethanol is required.
- the 100% Alcohol is decanted into an appropriate waste container.
- the container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry).
- the tissue cassettes are transferred into an appropriately sized container with 100% Ethanol (ensuring that the volume of the 100% Ethanol reaches above the tissue cassette) and incubated between 30 to 40 minutes at Room Temperature.
- the 100% Alcohol is decanted into a sink with running water.
- the container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry).
- the tissue cassettes are transferred into an appropriately sized container with SafeClearTM and the volume of the SafeClearTM made to reach above the tissue cassette and incubated between 30 to 40 minutes at room temperature.
- the SafeClearTM is decanted into a sink with running water.
- the container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry).
- the tissue cassettes are placed into an appropriate container with SafeClearTM, ensuring that the volume of the SafeClearTM reaches above the tissue cassette.
- the tissue cassettes are incubated between 30 to 40 minutes at room temperature.
- the incubator/shaker was set at 65 °C, ensuring that the shaker switch is in the OFF position. Equal volumes of melted paraffin were added with SafeClear and placed in a 65 °C + 1 °C incubator.
- the container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry).
- the tissue cassettes are transferred into an appropriate container with 50:50 Paraffin/SafeClearTM, ensuring that the volume of the 50:50 Paraffin/SafeClearTM reaches above the tissue cassette, and incubated between 30 to 40 minutes at 65 °C + 1 °C. (Ensuring the Shaker switch is in the OFF position).
- the 50:50 Paraffin/SafeClearTM was decanted into a disposable container.
- the tissue cassette was transferred into an appropriate container with Paraffin (ensuring that the volume of the Paraffin reaches above the tissue cassette), and incubated between 60 to 80 minutes at 65 °C + 1 °C.
- the Shaker switch is in the OFF position.
- the Paraffin was decanted into a disposable container.
- the tissue cassette was transferred into an appropriate container with Paraffin (Ensure that the volume of the Paraffin reaches above the tissue cassette), and incubated between 60 to 80 minutes at 65 °C + 1 °C (Ensure Shaker switch is in the OFF position).
- the Paraffin is decanted into a disposable container.
- the tissue cassette is transferred into an appropriate container with sample reservoir of the Paraffin Embedder (ensuring that the volume of the Paraffin reaches above the tissue cassettes) and incubated between 120 to 140 minutes.
- Paraffin embedding is performed as described herein. After incubation, the first tissue cassette is removed and placed on a paraffin embedder. Tissue molds are placed into the warmed tissue mold holder. Mini-cylinders are inspected to ensure that they are intact and have significantly shrunk in size. The tissue mold is removed from the tissue mold warmer and paraffin dispensed from a nozzle to fill the bottom of the well. The tissue mold containing paraffin is placed over the cold portion of the paraffin embedder.
- a mini-cylinder is placed onto the center of the tissue mold and allowed to cool partially, but not until solid.
- the tissue cassette is placed without the lid over the tissue mold with the flat surface facing the tissue.
- the tissue cassette is placed downward (ensure that no air bubbles are trapped within the sample). If air bubbles are present, the tissue cassette is lifted and placed back down until all the air bubbles are removed (ensure that the mini- cylinder is still within the center of the tissue mold).
- Paraffin is dispensed from the nozzle until the entire bottom of the tissue cassette is covered. Material is carefully transferred and placed on the cold side of the paraffin embedder. This is repeated until all of the mini- cylinders are embedded in paraffin.
- the embedded cylinders are allowed to cool for a minimum of 30 minutes up to a maximum of 24 hours on the cold side of the embedder. If the material is going to be filled within the next 24 hours, the bulk material is stored at 2-8°C until filled. If the material is not going to be filled within the next 24 hours, the bulk material is stored at the appropriate storage temperature.
- These procedures may also be used to assay markers of unknown significance or known, but experimental (e.g., not diagnostic), significance (e.g., for basic research purposes).
- cells expressing any marker of interest may be used in place of and / or in addition to luciferase-expressing cells and assayed as desired.
- Multiple (e.g., four) cylinders containing cells where about 90% of such cells are engineered to express luciferase and about 10% are "wild-type" cells (e.g., do not express luciferase) are manufactured using the methods of Examples 1 A and 2 using the exemplary bulking agent RBCs. Multiple (e.g., 10-15) blocks are manufactured from each cylinder.
- Sections are cut from blocks, DNA extracted, and the DNA amplified using the TaqMan Mutation Detection Assays (castPCRTM assays) for the luciferase and wild-type sequences.
- the luciferase percentage is then calculated using the procedure described in Example 2. This system is useful for basic research purposes as cells expressing any sequence of interest may be used in place of the luciferase-expressing cells.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This specification relates to Formalin-fixed embedded quality control material containing a bulking agent for use for validation, verification, and to run controls for molecular assays. The quality control material can be used for a variety of tissues and for a variety of molecular assays. The quality control material can be used in commercial labs for validation and limit-of-detection analyses.
Description
Method for Preparing FFPE Quality Control Material with Bulking Agent
BACKGROUND
[0001] Routine processing of tissue samples in the clinical setting involves formalin fixation and paraffin embedding. FFPE is a highly efficient method that is currently the standard in pathology laboratories. Formalin-fixed, paraffin-embedded (FFPE) tissues may be stored indefinitely at room temperature, and nucleic acids (both DNA and RNA) may be recovered from them decades after fixation, making FFPE tissues an important resource for molecular assays. However, better methods for developing FFPE materials that mimic patient specimens are needed to monitor the performance of molecular assays from FFPE materials and to develop appropriate quality control materials for these assays.
SUMMARY
[0002] This disclosure relates to reagents and methods for preparing formalin-fixed, paraffin- embedded (FFPE) samples by combining test cells and / or tissues with a bulking agent having a physical differentiating feature from the test cells to provide a test mixture and preparing a FFPE sample therefrom. In certain embodiments, the bulking agent improves the visibility and / or uniformity of the test cells in the sample as compared to a sample prepared in the absence of the bulking agent, determined visually (e.g., able to be seen by the naked eye and differentiated from the test cells). In certain embodiments, the bulking agent comprises particles having a physical differentiating feature from the test cells. In some embodiments, the particles are substantially the same size as the test cells and may be, for example, control cells. The physical differentiating feature may be, for instance, color which may, in some instances, be provided by a detectable label (e.g., fixably attached to the particles). In certain embodiments, the particles may not comprise a nucleus, DNA (e.g., nuclear DNA), and / or RNA (e.g., microRNA (miRNA), messenger RNA (mRNA)). Typically, the test cells comprise a genetic marker not detectable and / or not present in the bulking agent. In some embodiments, the bulking agent consists essentially of control cells and / or may be and / or may comprise red blood cells (RBCs). In some embodiments, this disclosure relates to formalin-fixed embedded quality control material for use in validation, verification, and as run controls for molecular assays. The quality control material can be used for a variety of tissues and for a variety of molecular assays. The quality control material can be used in commercial labs for validation or verification, including limit-of-
detection analyses, precision analyses, and accuracy analyses. These and other features of the present teachings will become more apparent from the description herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0003] The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.
[0004] FIG. 1A shows an FFPE block manufactured with and without red blood cells.
FIG. IB shows an FFPE block manufactured with red blood cells for processing DNA or RNA.
[0005] FIG. 2 show FFPE sections in SafeClear during deparaffinization.
DETAILED DESCRIPTION
[0006] This disclosure relates to reagents and methods for preparing formalin-fixed, paraffin- embedded (FFPE) samples by combining test cells and / or tissues with a bulking agent having a physical differentiating feature from the test cells to provide a test mixture and preparing a FFPE sample therefrom. Some embodiments described herein provide highly reproducible FFPE methods that provide for detection of one or more markers as described below. For example, the use of the methods described herein with nucleic acid-based assays may allow for more efficient (e.g., simpler process, less time) isolation of nucleic acid (e.g., DNA, RNA) from the FFPE with an amount of degradation in the sample that mimics the in the assay. In this manner, a more accurate control is provided to the assay. In some embodiments, the samples prepared as described herein may serve as quality control material that may be used to validate, verify and / or provide controls for nucleic acid-based assays. Such quality control material may be used for a variety of tissues and in a variety of assay systems (e.g., including but not limited to limit-of-detection analyses, precision analyses, and accuracy analyses). The methods described herein provide highly reproducible FFPE methods that provide for detection of one or more markers. Further, these methods allow for a quality control FFPE product that includes test cells containing at least one test marker in a background of bulking agent that comprises at least one physical differentiating feature from the test cells (e.g., particles such as cells (e.g., red blood cells (RBCs)). Laboratories performing FFPE-based molecular diagnostic tests typically use synthetic oligonucleotides, cell lines, genomic or plasmid DNA, or patient specimens as quality control material.
However synthetic material, cell lines, and genomic or plasmid DNA may not control for specific steps in the process. Patient specimens are often limited in quantity and inconsistent between sections, reducing the utility of the control material for monitoring trending over an extended period of time. A FFPE quality control material that mimics FFPE tissue and is homogenous and consistently produced lot-to-lot ensures that laboratories have access to a full process control that can be used over an indefinite period to monitor assay performance. The methods are highly reproducible within a lot and from lot-to-lot and provide for detection of one or more markers as described herein.
[0007] In certain embodiments, the bulking agent may improve the visibility and / or uniformity of the test cells in the sample as compared to a sample prepared in the absence of the bulking agent. The "visibility" of a sample may be determined by any method available to those of ordinary skill in the art including, for example, visual inspection to identify and / or count cells within the sample and / or a particular area thereof. Visibility typically refers to able to be seen by the naked eye and differentiated from the test cells. Thus, visibility may be determined with respect to the number and / or type of cells and / or particles present within a particular area of the sample determined, for instance, visually, such that one type of cell and / or particle may be differentiated from another type (e.g., from test cells). "Uniformity" may be similarly determined with an emphasis on whether the test cells and / or particles are, for instance, sufficiently and / or substantially evenly spaced (e.g., distanced) from one another within the sample and/or if the cells in the FFPE section retain the shape expected from the mold (e.g., without noticeable distortion, other than shrinkage in size). A uniform sample may be one in which the test cells and / or particles are not present in "clumps" (e.g., areas of high cell and / or particle concentration) and / or where areas of the sample are devoid of test cells and / or particles. These determinations may be accomplished manually (e.g., using a microscope) or with the aid of an automated device to determine the number of cells present in each FFPE section.
[0008] In certain embodiments, the bulking agent may comprise particles having one or more "physical differentiating features" from the test cells. A suitable physical differentiating feature may be, for instance, color, size and / or another detectable "marker". The physical differentiating feature may be, for instance, a difference in color that may, in some instances, be provided by the color (e.g., de novo) of the particle (e.g., encased colored particle, cell such as an RBC) and / or a detectable label (e.g., fixably attached to the particles). Thus, the
bulking agent may comprise or be a colored substance. The colored substance could include dyes, pigments, or proteins. Examples include, but are not limited to hemoglobin, melanins (e.g., eumelanin or pheomelanin), bilirubin, biliverdin, carotene, chlorophyll, anthocyanins, or carotenoids. In some embodiments, the particles may be of substantially different or substantially the same size as the test cells (e.g., another physical differentiating feature). In some embodiments, the bulking agent may be any material that is between about any of 0.5 nm to 200 μιη in diameter, for instance. In some embodiments, the test cells comprise one or more markers not detectable and / or not present in the bulking agent. The particles may also contain and / or lack a "genetic" marker (e.g., a "target sequence" such as a nucleic acid (DNA, RNA) and / or expressed protein) that is absent and / or present, respectively, in the test cells. A genetic marker may be "present" by either existing or being expressed within and / or by the particle (e.g., the genome, cytoplasm, or surface of a cell). Such a marker may be naturally present within the particle (e.g., a cell) or the particle may be manufactured to include the same. A particle (e.g., a cell) may also be modified such that a naturally present marker is removed therefrom (e.g., by deletion of a DNA sequence from the genome of the cells). For instance, in certain embodiments, the particles may or may not comprise a nucleus, any or any particular type of DNA (e.g., nuclear DNA), and / or any particular type of RNA (e.g., microRNA (miRNA), messenger RNA (mRNA)) while the test cells conversely do or do not, respectively, comprise such components. Thus, for example, the particle (e.g., cell) may lack a DNA sequence that is present in the test cells. In some embodiments, for instance, the bulking agent may consist essentially of particles that are control cells (e.g., mammalian cells) that express a physical differentiating feature from the test cells. Exemplary bulking agents, particles and / or cells include but are not limited to red blood cells, non-human cells such as bacterial, yeast, plant, or animal cells that have a color and / or do not contain the marker of interest. For instance, the bulking agent may be and / or comprise red blood cells (RBCs) where the test cells are mammalian cells (e.g., as described in the Examples section). In such embodiments, the physical differentiating feature may be color (e.g., where, unlike the RBCs the test cells are not red in color). Other suitable particles are also contemplated for use in these methods, as could be determined by one of ordinary skill in the art.
[0009] In certain embodiments, the methods described herein may be used to solve problems associated with the preparation of FFPE material. For instance, to generate formalin fixed and paraffin embedded quality control material, typically a synthetic tissue is created. Such
synthetic tissue typically includes the steps of obtaining a defined concentration of cellular material; mixing the cellular material with a gelling polymer to create a gel/cellular material; adding the gel/cellular material to a mold (e.g., a polypropylene cylinder) with a defined shape until the gelling polymer solidifies; and, slicing the solidified material to a uniform and defined size. In some embodiments, the methods also include formalin fixing the sliced solidified material. In some embodiments, the methods also include embedding the material in paraffin. In some embodiments, the cellular material includes test cells and one or more bulking agents. In some embodiments, the cellular material comprises a known number of test cells and one or more bulking agents (e.g., a known amount) in a homogeneous mixture. In some embodiments, the test cells may comprise at least one marker to be detected that is not present in the bulking agent (e.g., one or more DNA and / or RNA sequences).
[0010] The sample (e.g., cell material) may comprise both test cells and bulking agent (e.g., particles, cells, RBCs) in known amounts of one or both of the test cells (e.g, optionally including background and / or control cells) and the bulking agent. In some embodiments, the mixture of test cells and bulking agent (e.g., particles, RBCs) consists of about 10~12 to about 100,000% bulking agent (e.g., in some embodiments, the lower limit may be about one bulking agent (e.g., particle) per 1010 test cells and the upper limit may be about one thousand bulking agents per test cell). In some embodiments, the mixture to be fixed may comprise about 10"12 to about 100,000% test cells (e.g., 10"12, 10~n, 10"10, 10"9, 10"8, 10"7, 10"6, 10"5, 10" 4, .001, 0.005, 0.006, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 (e.g., which equals a 1 : 1 ratio of test cells to bulking agent (e.g., RBCs)), 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2500, 5000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000 or 100,000% test cells (e.g., relative to the bulking agent (e.g., cells such as RBCs)). In some embodiments, the amount of the test cells in the mixture is less than the amount of bulking agent in the mixture.
[0011 ] Typically, a defined concentration of test cells is admixed with a defined concentration of bulking agent (e.g., particles such as cells), admixed with a gelling polymer, and formalin-fixed. This process also typically involves dehydration, clearing and infiltration
steps. During any of these steps, the synthetic tissue may shrink in size or become otherwise deformed, resulting in a sample that is difficult to further process. For example, the shrinkage of a synthetic tissue with a low cell concentration (e.g., approximately 1 x 107 cells/mL or less including but not limited to any of approximately 106, 105, 104, 103, 102 or 10 cells/ml) may not be uniform as the tissue may not retain its original shape. This problem may be solved using the methods described herein. In the examples, a bulking agent (RBCs) was added to the cellular material containing the target for the diagnostic assay system and observed to reduce shrinkage and improve uniformity. RBCs were selected because these may be processed similarly to test cells, but do not contain a nucleus and therefore do not contain nuclear DNA. Accordingly, the marker of interest (e.g., target of interest, the KRAS sequence in the Examples) is not present in the RBCs. In this way, the bulking agent was used to increase the total cell concentration of the sample for processing without diluting the target of interest.
[0012] In certain embodiments, the sample may comprise test cells (e.g., a defined concentration of test cells) admixed with the bulking agent (e.g., a defined concentration of particles (e.g., cells such as RBCs)), where the test cells comprise one or more markers (e.g., color, size, nucleic acid-, protein-, carbohydrate-, and / or lipid-based marker) and the bulking agent does not comprise the one or more markers. That marker is typically considered a differentiating feature or, more specifically, a physical differentiating feature. In some embodiments, the test cells may be cancer cells. In some embodiments, the test cells are a mixture of cancer cells and non-cancer cells. In some embodiments, the test cells are non- cancer cells. For instance, the test cells may be derived from a biopsy. Thus, the sample may comprise, for instance, cells having and / or expressing a genetic marker (e.g., a target sequence) of cancer such as a SNP (single nucleotide polymorphism), insertion, deletion, translocation, fusion, CNV (copy number variation) etc, and cells lacking and / or not expressing that genetic marker (e.g., a cell line containing the wild-type allele). The cell mixtures may be mixed with a suitable excipient (e.g., agarose) and a bulking agent (e.g., RBCs) and aliquoted into a suitable mold (e.g., a polypropylene cylindrical mold). The cell- excipient mixture may then be allowed to solidify (e.g., in the form of a cylinder), the resultant product removed therefrom, and placed on a sterile surface. A slicing apparatus may then be used to slice the cylinder into equal parts. Each part may then be formalin fixed and embedded according to standard procedures (e.g., as in the Examples herein). Lastly, a microtome may be used to slice the FFPE blocks into sections of defined thickness that may
be placed into vials or onto microscope slides. The resulting FFPE slice can be referred to as the quality control (QC) sample. In some embodiments, each of the above-described steps may or may not be distinct steps (e.g., one or more steps may be combined), may or may not include additional steps not listed, and / or may also comprise less than all of these steps.
[0013] Commonly, FFPE specimens require processing steps prior to analysis. These steps can include, without limitation: deparaffinization, reversal of cross linking, extraction, nucleic acid yield test, and amplification/detection. These may be accomplished using any suitable techniques, which are well known to those of ordinary skill in the art.
[0014] In some embodiments, the genetic marker may relate to any one or more of the cells lines, mutations and / or genes listed in Tables 1 and 2. These are non-limiting examples of genetic markers. One of skill in the art will appreciate that any genetic marker can be incorporated into the compositions and methods disclosed herein.
Table 1
Cell lines and KRAS mutations
Table 2
Exemplary Markers
ARID 1 A ERBB4 KDM5C PPP2R1A
ARID2 ERCC1 KDM6A PRDM1
ASXL1 ERG KDR PRKARIA
ATM ESR1 KEAP1 PRKDC
ATR EZH2 KIT PTCH1
FAM123B
ATRX (WTX) KLHL6 PTEN
AURKA FAM46C KRAS PTPN11
AURKB FANCA LRP1B RAD50
AXL FANCC MAGOH RAD51
BAP1 FANCD2 MAP2K1 RAF1
BARD1 FANCE MAP2K2 RARA
BCL2 FANCF MAP2K4 RBI
BCL2L2 FANCG MAP3K1 RET
BCL6 FANCL MAPK1 RHEB
BCOR FBXW7 MAX RHOA
BCORL1 FGF10 MCL1 RICTOR
BLM FGF14 MDM2 RNF43
BRAF FGF19 MDM4 RPTOR
BRCA1 FGF23 MED 12 RUNX1
BRCA2 FGF3 MEF2B SETD2
BRIP1 FGF4 MEN1 SF3B1
BTK FGF6 MET SMAD2
CARD 11 FGFR1 MGMT SMAD4
CBFB FGFR2 MITF SMARCA4
CBL FGFR3 MLH1 SMARCB1
CCND1 FGFR4 MLL SMO
CCND2 FLT1 MLL2 SOCS1
CCND3 FLT3 MPL SOX10
CCNE1 FLT4 MRE11A SOX2
CD79A FOXL2 MSH2 SPEN
CD79B GABRA6 MSH6 SPOP
CDC73 GABRG2 MTOR SRC
CDH1 GATA1 MUTYH STAG2
CDK12 GATA2 MYC STAT3
CDK4 GATA3 MYCL1 STAT4
CDK6 GID4 (C17orf39) MYCN STK11
CDK8 GNA11 MYD88 SUFU
CDKN1B GNA13 NBN TET2
CDKN2A GNAQ NF1 TGFBR2
CDKN2B GNAS NF2 TNFAIP3
CDKN2C GPR124 NFE2L2 TNFRSF14
CEBPA GRIN2A NFKBIA TOPI
CHEK1 GSK3B NKX2-1 TP53
CHEK2 HGF NOTCH 1 TSC1
CIC HNF1A NOTCH2 TSC2
CREBBP HRAS NPM1 TSHR
CRKL IDH1 NRAS U2AF1
CRLF2 IDH2 NTRK1 VHL
CSF1R IFITM1 NTRK2 WISP3
CTCF IFITM3 NTRK3 WT1
CTNNA1 IGF1R NUP93 XPOl
CTNNB1 IKBKE PAK3 ZNF217
DAXX IKZF1 PALB2 ZNF703
DDR2 IL3RA PARP1 BRAF-1799TA
CTNNB1-121AG CTNNB1-134CT EGFR-2369CT KRAS-34GA
KRAS-35GA KRAS-38GA KRAS-176CG KRAS-183AC
NRAS-35GA NRAS-38GA NRAS-181CA NRAS- 183 AT
TP53-524GA TP53-637CT TP53-721TG TP53-733GA
TP53-742CT TP53-743GA TP53-817CT -
[0015] Additionally suitable markers may include, for instance, allele- specific and / or cell type-specific biomarkers. For example, common solid tumors such as breast, lung, prostate, colorectal, thyroid and pancreatic tissues are of predominantly epithelial cell origins. Several biomarkers for tumor cells of epithelial origins may include, for instance, one or more of cytokeratin, EPCAM, ICAM, etc., or cancer related markers, including CEA (carcinoembryonic antigen). Similarly, prostate cancer cells usually express prostate-specific antigen (PSA). Allelic variants may include, by way of non-limiting example, BRAF- 1799TA, CTNNB 1-121 AG, CTNNB1-134CT, EGFR-2369CT, EGFR-2573TG, KRAS- 34GA, KRAS-35GA, KRAS-38GA, KRAS-176CG, KRAS-183AC, NRAS-35GA, NRAS- 38GA, NRAS-181CA, NRAS- 183 AT, TP53-524GA, TP53-637CT, TP53-721TG, TP53- 733GA, TP53-742CT, TP53-743GA, TP53-817CT, and the like as described in, for example, US 2010/0221717 Al (U.S. Ser. No. 12/641,321) and US 2010/0285478 Al (U.S. Ser. No. 12/748,329). As used herein, the term "allele" refers generally to alternative DNA sequences at the same physical locus on a segment of DNA, such as, for example, on homologous chromosomes. An allele can refer to DNA sequences which differ between the same physical locus found on homologous chromosomes within a single cell or organism or which differ at the same physical locus in multiple cells or organisms ("allelic variant"). In some instances, an allele can correspond to a single nucleotide difference at a particular physical locus. In
other embodiments and allele can correspond to nucleotide (single or multiple) insertion or deletion. These markers are normally not found or expressed (or expressed in much lower level) in normal circulating blood cells (e.g., the exemplary bulking agent RBCs).
[0016] Any one or more of these cells lines and / or markers may be used alone and / or in combination with one another. Multiplex molecular assays allow for the detection of multiple test cells. Therefore, further embodiments include the step of pooling samples to be tested prior to using the multiplexed assays described herein. For example, different slices with individual mutations can be placed together in 1 tube (to be processed together). For example and without limitation, 1 slice from the G12V and 1 slice from the G12D mutations could be placed together to make a multiplex control (e.g., Table 7). Other markers may also be suitable as would be understood by those of ordinary skill in the art and any number of markers can be combined to produce a multiplex control. For instance, the marker may be any marker known in the art and can be used to perform cancer research, diagnose disease, prognosticate disease and/or to test disease for drug effectiveness.
[0017] The sample (e.g., cell material) and / or bulking agent to be processed by the methods described herein may be obtained from any cell, tissue or organ of any type of organism. The cell material may include one or more prokaryotic cells and / or one or more eukaryotic cells including but not limited to a protozoa, fungus, plant, animal (e.g., human). The cells may be, for instance, hematopoietic cells. The cells may be cancer cells and / or infected cells. The cells may be tissue culture cells. The cells may also be obtained from a biopsy. In some embodiments, a tissue sample is disrupted into cells to prepare a homogeneous material for FFPE processing.
[0018] In some embodiments, the sample (e.g., cell material) contains test cells. The test cells may be cells that contain and / or express and / or are considered "positive" for one or more particular marker or markers that are not present in the bulking agent (e.g., particles (e.g., cells)). In some embodiments, the cell material may contain more than one type of test cell. For example, if two different markers are diagnostic for a particular disease, two different test cells may be included, with one test cell being positive for one marker and the other test cell being positive for a second marker. In some embodiments, the sample may also contain a bulking agent. In some embodiments, the cell material can contain background cells (e.g., cells that do not contain the marker and/or contains a wild-type marker instead). The background cells may make up between, for example, about 1 to about 99.9% (e.g.,
about any of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97.5, 99, 99.5 or 99.9%) of the cells in the sample. The background cells may be fixed or unfixed along with or when added to the test cell and / or bulking agent mixture. In at least one embodiment, the test cells and bulking agent may be mixed and then fixed to form a mixture for processing. In certain embodiments, the test cells may be fixed and then mixed with the one or more bulking agents for preparation of FFPE blocks. In some embodiments, the test cells may be fixed and the bulking agent may be fixed or unfixed in the mixture. In some embodiments, the test cell and bulking agent can be mixed before fixation. In some embodiments, the test cell and the bulking agent can be mixed after the cells are fixed. In some embodiments, the cell material is a formalin fixed (or other fixed) sample and/or an FFPE sample of tissue. In this case, because it would be difficult or impossible to disrupt the FFPE tissue into separate cells, the cell material can be used for a positive or negative control. In embodiments where the cells are unfixed, they may be frozen. In certain embodiments, cells can be mixed with polymer, solidified and then frozen. When this technique is used, an agent, such as glycerol may be added to the polymer to prevent cracking.
[0019] In certain embodiments, the bulking material can be synthetic. Any suitable synthethic particles can be used. Nonlimiting examples include: 3000 Series NANOSPERE size standards, 4000 Series Monosized particles, 3K/4K Series Particle Counter Standards, 4D Seried Dry Microsphere Size Standards, and 8000 Series Silica Particle Size Standards (Thermo Fisher Scientific).
[0020] The excipient or excipients used to create the solidified mixture of test cells and bulking agent may comprise a gel (e.g., any colloidal suspension of a solid dispersed in a liquid). A suitable excipient may be any gel that may be mixed with test cells without changing the properties of the test cells such that the parameter being tested (e.g., the presence and / or expression and / or character of a particular nucleic acid, protein, carbohydrate and / or lipid) cannot be, or is at least less efficiently or more difficult to assay. A suitable gel, for example, may be any gel that can change from a liquid or semi-solid state (suitable for mixing with test cells) to a solid or gelled state (e.g., such that it may be sliced). In some embodiments, the gel may be an agarose, agar, carageenan, pectin, egg yolk, any type of polymer, and / or mixtures thereof. In some embodiments, the gel is a polymer that may be solidified or hardened (e.g., using a cross-linking agent, motion and / or temperature).
Solidified or hardened refers to the ability of a gel to be converted from a liquid or semi- liquid state to a solid or semi-solid state. Temperature- solidified gels (e.g., a polymer is introduced into a tube in a fluid form, then allowed to gel to a solid form by cooling within the tube) may also be suitable. Most suitable of these types of gels are those that do not require an amount of heat to that would be detrimental to the test cells and / or the bulking agent(s). In addition, suitable gels may or may not contain inhibitory substances. In some embodiments, the gel does not contain an inhibitory substance that may inhibit the fixation, embedding, or downstream molecular tests. However, in other embodiments, a pre-defined concentration of inhibitor could be added such as typically found in a human specimen. For example, heme molecules from red blood cells can inhibit PCR. A gel containing heme molecules therefore could serve as a control for extraction step efficiency in an assay if the concentration therein in comparable to a normal human sample. Other excipients are also contemplated as would be understood by those of ordinary skill in the art.
[0021 ] The mold can be any shape known to the skilled artisan that allow for slicing. In some embodiments, the shape of the mold can be a cylinder. The cylinder can be of any length and diameter such that a useful sized slice is produced. The cylinder can be made of any material that will keep its shape when a hot gel is poured into it. In some embodiments, the material will not stick to the gel/cellular material mixture. In some embodiments, the material will not affect the cellular integrity. In some embodiments, the material can be removed from the solidified gel/cellular material mixture. In some embodiments, the material can be removed without sticking to the gel/cellular material mixture. In some embodiments, the ends of the cylindrical material can be cut off and the tube of hardened gel/cellular material can be slid out. Materials may include, for instance, polypropylene and equivalent plastic materials. Other materials can be envisioned that might require producing a mold that can be opened and closed, for example glass, metals, and very hard plastics. The cylindrical solidified gel/cellular material can then be sliced into sections of a uniform and defined size. This ensures that the amount of nucleic acid in each slice will be equivalent. The cylindrical solidified gel/cellular material mixture may be sliced using any method known in the art that results in slices of uniform and defined sizes. In some embodiments, the slicer may be a modified egg slicer, modified so that the base is removed and the tines (e.g., which are equidistant from each other) are more easily usable. Any slicer with equidistant slicing ability could be used. In some embodiments, the slicing wires or blades are spaced 1 mm to 5 mm apart. In some embodiments other methods of providing for
equivalent samples (e.g., slices) are used. Any tool can be used that provides a sample with a constant volume. Exemplary methods include using a tool to obtain a plug, or using a syringe to obtain an even amount of liquefied sample (e.g., liquefied gel/cellular material).
[0022] Chemical fixatives are used to preserve tissue from degradation, and to maintain the structure of the cell and of sub-cellular components such as cell organelles (e.g., nucleus, endoplasmic reticulum, mitochondria) and may be used in the methods described herein. The most common fixative for FFPE is neutral buffered formalin (4% formaldehyde in phosphate buffered saline). Fixatives preserve tissues or cells mainly by irreversibly cross-linking proteins. The main action of these aldehyde fixatives is to cross-link amino groups in proteins through the formation of CH2 (methylene) linkage, in the case of formaldehyde, or by a C5H10 cross-links in the case of glutaraldehyde. This process, while preserving the structural integrity of the cells and tissue can damage the biological functionality of proteins, particularly enzymes, and can also denature them to a certain extent. This can be detrimental to certain histological techniques. The sliced solidified gel/cellular material may be immersed in a fixative, such as a solution with a protein crosslinking activity, such as but not limited to a formaldehyde solution, glutaraldehyde solution, formaldehyde-alcohol mixed solution, alcohol solution, Bouin's solution, Zenker solution, Hely solution, osmic acid solution, Carnoy solution, standard saline citrate (SSC) and RNAeasy™, and equivalents thereof. In some embodiments, the fixative is formalin. In some embodiments, the formaldehyde can be in any kind of buffer. Non-limiting examples of fixative alcohols include thanol and isopropanol. These fixatives are commercially available. The time of fixation may be from any of about 0.5 to about 72 hours, including but not limited to about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, and 71 hours. The temperature of fixation can be from about 4°C to about 26°C, including but not limited to, any of about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25°C. Other conditions for fixation are also contemplated as would be understood by those of ordinary skill in the art.
[0023] After the slices have been fixed, an embedding step may be carried out. During this process the tissue samples are placed into molds along with liquid embedding material (such as agar, gelatin, or wax) which is then hardened. This is achieved by cooling in the case of
paraffin wax and heating (curing) in the case of the epoxy resins. The acrylic resins are polymerized by heat, ultraviolet light, or chemical catalysts. The hardened blocks containing the tissue samples are then ready to be sectioned. Because formalin-fixed, paraffin- embedded (FFPE) tissues may be stored indefinitely at room temperature, and nucleic acids (both DNA and RNA) may be recovered from them decades after fixation, this makes FFPE tissues an important resource for historical studies in medicine. Embedding can also be accomplished using frozen, non-fixed tissue in a water-based medium. Pre-frozen tissues are placed into molds with the liquid embedding material, usually a water-based glycol, OCT, TBS, Cryogel, or resin, which is then frozen to form hardened blocks. The resulting blocks can be sectioned using methods known in the art, including, but not limited to, microtomes, vibratory microtomes and cryostats and the like.
[0024] An exemplary method comprises:
Cell polymer cylinder -> egg slicer -> mini cylinder -> FFPE process -> FFPE blocks - Microtome for sectioning - FFPE sections
[0025] Sections may be deparaffinized using methods known in the art and/or commercially available kits. The methods remove the bulk of paraffin from the sample. Various techniques are known for deparaffinizing and include, but are not limited to, washing with an organic solvent or agent to dissolve the paraffin. Solvents may include but are not limited to, benzene, toluene, ethylbenzene, xylenes, D-li-monene, octane, and mixtures thereof. These solvents are preferably of high purity, usually greater than 99%. The volume used and the number of washes necessary will depend on the size of the sample and the amount of paraffin to be removed. A sample may be washed between 1 and about 10 times, or between about two and about four times. A typical volume of organic solvent is about 500 ml for a 10 mm tissue sample. After deparaffinization, samples are preferably wash such as by step-wise washing with aqueous lower alcoholic solutions of decreasing concentrations. Ethanol is a preferred lower alcohol for wash while other alcohols may also be used. Non-limiting examples include methanol, isopropanol, and other C1-C5 alcohols. The sample is alternatively vigorously mixed with alcoholic solutions followed by its removal. In one embodiment, the concentration of alcohol is stepwise lowered.
[0026] The sections may be used to isolate DNA or RNA for identification of the presence of a marker and/or for expression of a marker using standard techniques. The markers can be
used for investigational purposes, diagnosis, prognosis, typing, and/or staging of disease. As described above, the marker(s) may include DNA or RNA (e.g., for the presence and / or expression levels thereof in test cells). Exemplary markers include, for instance, the genes (or proteins expressed therefrom) listed in Table 2. Gene expression analyses of various tumor types (breast, lung, prostate and colon) have revealed that there exist numerous subtypes of tumors within each anatomically defined cancer. Furthermore, in some of these studies different subtypes have been linked to a particular prognosis. For example, Wigle et al, (2002 Cancer Research 62 (11) pp. 3005-3008) and Beer et al., (2002 Nature 8 (8) pp. 816-824) demonstrated the existence of particular clusters of genes that are correlated with different disease-free survivals in non-small cell lung cancer. These reports establish that the molecular "make-up" of tumors, as defined by gene expression profiles, has a direct correlation to clinical endpoints such as disease free survival. These retrospective studies strongly suggest that in going forward with prospective trials there is great promise that the molecular make-up of a given tumor will also be directly correlated with whether a patient will respond or not respond to a given therapy. Pharmacogenomic methods can identify patients likely to respond to a particular drug and can lead the way to new therapeutic approaches. For example, thymidylate synthase (TS) is an integral enzyme in DNA biosynthesis where it catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) and provides the only route for de novo synthesis of pyrimidine nucleotides within the cell (Johnston et al., 2002, J. Clinical Oncology, 20(7) pp. 1721-1728). Thymidylate synthase is a target for chemotherapeutic drugs, most commonly the antifolate agent 5-fluorouracil (5-FU). As the most effective single agent for the treatment of colon, head and neck and breast cancers, the primary action of 5- FU is to inhibit TS activity, resulting in depletion of intracellular thymine levels and subsequently leading to cell death. Other markers that can be tested for include, but are not limited to: HIPl in the diagnosis and treatment of lymphoma and brain cancers; TS and/or ERCC1 expression levels prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies; recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer; ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Hematopoietic cancers or metastases may also be tested using the reagents and methods described herein (e.g., QC FFPE controls). Cancers which involve cells generated during hematopoiesis, a process by which cellular elements of blood, such as lymphocytes, leukocytes, platelets, erythrocytes and natural killer cells are generated are referred to as hematopoietic cancers. Lymphocytes
which can be found in blood and lymphatic tissue and are critical for immune response are categorized into two main classes of lymphocytes: B lymphocytes (B cells) and T lymphocytes (T cells), which mediate humoral and cell mediated immunity, respectively. Many of these cancers are characterized by recurrent translocations that can be detected from FFPE using methods discussed herein.
[0027] Many different types of DNAs and RNAs may be detected using the methods described herein. Exemplary DNA molecules may include, for instance, genomic DNA, mitochondrial DNA, cDNA or other DNA. Exemplary RNAs that may be detected may include, for example, messenger RNA (mRNA), non-coding RNA (including long non- coding RNA), antisense RNA, CRISPR RNA, microRNA, small-interfering RNA (siRNA), pathogen-associated RNAs (e.g., bacterial or viral RNAs), and the like. Such RNA molecules may be detected using any of the available methods of detection including, for example, next generation sequencing (NGS), RT-PCR, microarray-based systems, and the like. In certain embodiments, a combination of cell lines can be detected. In some embodiments, a plurality of cell lines can be utilized in equal or unequal proportion. For example, a plurality (i.e., 2 or more) of cell lines can be combined in equal proportion wherein each contains a different fusion mRNA gene, thereby providing an FFPE fusion control material.
[0028] This disclosure further relates to kits comprising one or more reagents for carrying out the methods described herein along with, optionally, instructions for use. A "kit," as used herein, may refer to a combination of at least one QC sample for FFPE prepared using the methods described herein (e.g., a FFPE slice of a gelled homogeneous mixture of test cells and bulking agent (e.g., RBCs)). Other aspects of this disclosure relates to kits that may be used to prepare samples for FFPE. In some embodiments, at least one quality control sample (e.g., including at least one type of test cell comprising a marker and at least one bulking agent comprising a physical differentiating feature) for FFPE may be made by the methods described herein and included in a kit. In some embodiments, the kit may also include multiple samples containing different types of test cells.
[0029] In some embodiments, the kit may contain a combination of QC samples organized in such a way as to provide controls for all variations of a particular marker. In some embodiments, the variations of the marker are variations of an oncogene that is diagnostic for a particular cancer (e.g., see Tables 1 and 2). In some embodiments, the variations of the
marker are variations of a mutation in a gene that are prognostic for the usefulness of treating with a drug. In some embodiments, the kit includes a number of different markers that are diagnostic of a particular cancer. In some embodiments, the marker or markers are for a particular disease. In other embodiments, the marker or markers are for a variety of diseases. In some embodiments, the marker or markers test for drug efficacy for a disease. In some embodiments, the marker or markers test for diagnosis of a disease or a group of related diseases. In some embodiments, the marker or markers test for a series of diseases that have common characteristics and/or symptoms. In some embodiments, for instance, the kit may comprise samples known to cover the breadth of mutations known for a particular cancer. In some embodiments, the marker may have unknown significance but may otherwise be of interest to the user (e.g., for basic research purposes). Other types of kits are also contemplated herein as would be understood by those of ordinary skill in the art.
[0030] The kit may also include a container (e.g., vial, test tube, flask, bottle, syringe or other packaging system (e.g., include injection or blow-molded plastic containers) into which a reagent may be placed / contained, and in some embodiments, aliquoted) for containing any one or more reagents of the kit. Where more than one component is included in the kit, it will generally include at least one second, third or other additional container into which the additional components can be separately placed. However, various combinations of components can be packaged in a single container. The kits may also include reagent containers in close confinement for commercial sale. When the components of the kit are provided in one and / or more liquid solutions, the liquid solution comprises an aqueous solution that can be a sterile aqueous solution. A kit can also include instructions for employing the kit components as well as the use of any other reagent not included in the kit. Instructions may include variations that can be implemented. The instructions may be provided as a separate part of the kit (e.g., a paper or plastic insert or attachment) or as an internet-based application. In some embodiments, the kit may contain QC FFPE samples for between any of about 1 to 1000 markers which may be detected alone or in combination with one another (e.g., a multiplex assay). In some embodiments, the kit may also comprise at least one other sample containing a defined concentration of a test cell admixed with the bulking agent at the concentrations described herein or otherwise found to be suitable. In some embodiments, the kit may include QC FFPE samples of various test cells to bulking agent ratios as described above. The kit may alternatively or also include, for instance, QC FFPE slices containing bulking agent and mixtures of wild-type to mutant test cells in
concentrations of about 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%. Exemplary kits are provided in Examples 3 and 4 herein. Other variations and arrangements for the kits of this disclosure are contemplated as would be understood by those of ordinary skill in the art.
[0031] In general, the following definitions may apply to the terms utilized in describing the reagents and methods of this disclosure. For instance, the term "FFPE" or "formalin fixed paraffin embedded" may refer to a method of treating tissues and/or cells by formalin fixing and paraffin embedding the tissues and/or cells and then slicing embedded material typically with a microtome. There are many methods known in the art for FFPE. As used herein, the phrase "quality control" ("QC") typically refer to a system for ensuring the maintenance of proper standards in methods to determine whether the process exhibits nonrandom variation. The terms "marker" and "test marker" may be interchangeable and may refer to a cellular component specific to a particular disease, whether of unknown significance, prognostic, diagnostic, and/or with reference to treatment. The marker may be a DNA, RNA, protein, carbohydrate and / or lipid marker. The marker may relate to any type of mutation associated with a disease. Markers may be associated with but are not limited to, translocations, alleles, single nucleotide polymorphisms (SNPs), expression profiles, etc. Such markers may relate to any type of nucleic acid including but not limited to DNA and / or RNA (mRNA, rRNA, tRNA, mitochondrial RNA). The markers may relate to genes, SNPs, microsatellites, translocations, alleles, mutations (e.g., multiple nucleotide and/or large deletions, additions, or changes), multi-RNA complexes, splice variants, transposons, ribozymes, microRNAs (primary, pre- or mature microRNAs), bacterial genomes, plasmids, viral genomes, and / or viroids. For example, in some embodiments, a DNA-based marker may be used to identify the presence of a SNP. In some embodiments, a RNA-based marker may be used to identify the expression of a SNP.
[0032] The terms "gelling polymer" or "gel" are interchangeable and may refer to a colloidal suspension of a solid dispersed in a liquid (e.g., a semi-rigid solid). The term "homogeneous" may refer to a mixture that exhibits uniformity. In the context of the mixture of test cells and bulking agent(s), the components may be intermixed in a uniform manner such that each portion (e.g., slice) contains approximately the same concentration of test cells and bulking agent as substantially any other portions (e.g., slices). As described herein, exemplary test cells may include but are not limited to, cancer cells, cells from a patient, cells
from a biopsy, hematopoietic cells, tissue culture cells, and / or cells of a tissue. As used herein, the terms "background cell", "negative cell", and / or "negative control" may be interchangeable and refer to a cell that does not contain the marker that is being tested for. In some cases, such a cell may be a wild-type cell of the same type as the test cell. The term "patient" may refer to any human or animal that is tested and/or treated for disease. The term "mold" may refer to a hollow cavity form or matrix into which a liquid or semi-liquid material is placed to take a desired shape upon cooling or drying. The term "test cell" may refer to a cell that is being tested to determine whether it contains one or more particular markers. The term "cylindrical" refers to something having the shape of a cylinder, an object shaped like a tube, an object or shape (e.g., rectangle, square, triangular cylinder) with straight sides and circular ends of equal size. The terms "solidified" and "hardened" may be used interchangeably and, with respect to a gel, refer to the ability of a gel to go from a liquid or semi-liquid state to a solid or semi-solid state. In the case of temperature- solidified gels, a polymer may be introduced into a cylindrical tube in a fluid form, then allowed to gel to a solid form by cooling. Gels may also be solidified by adding a cross-linker, by motion, and/or by other methods known to those of skill in the art. When using a gel mixed with a cell, it is of interest to choose a gel that does not require extreme heat to form a liquid since this will be detrimental to the cells. The term "fix" may refer to a method of preserving cells or tissue, which may include the irreversible cross-linking of proteins on and / or within cells.
[0033] It is to be understood that the descriptions of this disclosure are exemplary and explanatory only and are not intended to limit the scope of the current teachings. In this application, the use of the singular includes the plural unless specifically stated otherwise. Also, the use of "comprise", "contain", and "include", or modifications of those root words, for example but not limited to, "comprises", "contained", and "including", are not intended to be limiting. Use of "or" means "and/or" unless stated otherwise. The term "and/or" means that the terms before and after can be taken together or separately. For illustration purposes, but not as a limitation, "X and/or Y" can mean "X" or "Y" or "X and Y". Whenever a range of values is provided herein, the range is meant to include the starting value and the ending value and any value or value range therebetween unless otherwise specifically stated. For example, "from 0.2 to 0.5" may mean 0.2, 0.3, 0.4, and 0.5; ranges therebetween such as 0.2-0.3, 0.3 - 0.4, 0.2 - 0.4; increments there between such as 0.25, 0.35, 0.225, 0.335, 0.49; increment ranges there between such as 0.26 - 0.39; and the
like. The term "about" or "approximately" may refer the ordinary meaning of the term but may also indicate a value or values within about any of 1-10 percent of the listed value.
[0034] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way. All literature and similar materials cited in this application including, but not limited to, patents, patent applications, articles, books, treatises, and internet web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety for any purpose. In the event that one or more of the incorporated literature and similar materials defines or uses a term in such a way that it contradicts that term's definition in this application, this application controls. While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art. Certain embodiments are further described in the following examples. These embodiments are provided as examples only and are not intended to limit the scope of the claims in any way.
EXAMPLES
[0035] Aspects of the present teachings can be further understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way. Tables 3-5 provide materials, consumable and instruments used in the following examples. The examples use the KRAS molecular markers to demonstrate the usefulness of the quality control FFPE methods. There are known mutations within the codon 12 and 13 of the KRAS gene that results in the loss of effectiveness of pharmaceutical therapies. Seven mutations (G12D, G12V, G12C, G12S, G12A, G12R, G13D) comprise 98.5% of known KRAS mutations that are involved in identifying the usefulness of chemotherapy on colorectal cancers. A cell line containing the KRAS G12C mutation was obtained and mixed with red blood cells as described in Example 1. The method using an exemplary bulking agent (RBCs) was compared to the method carried out without a bulking agent, as described below.
[0036] The method including RBCs was found to promote uniformity of the cell-containing polymer (referred to as the synthetic tissue) during the FFPE process. This improves the ease
of manufacturing FFPE controls and increases the yield of the number of sections per block due to the increased size. The method including RBCs also improved the ease of extraction because the cell pellet was easier to see in the tube after deparaffinization.
Table 3
Materials
Table 4
Quality Control FFPE method using KRAS marker G12C
[0037] This example demonstrates the feasibility of manufacturing qualitative formalin-fixed paraffin embedded (FFPE) KRAS Positive Control products using the method herein with red blood cells. The study demonstrates the ability to manufacture and value assign stock materials from sourced raw materials, the reproducibility of the product, detection of the product on target assays, as well as comparison of the products' DNA quality to those of the old FFPE method. The cell line having the KRAS G12C mutation (SW1463) was obtained from ATCC (Manassas, VA) and grown to a total of 1.0 x 109 cells. Stock materials are manufactured in Cell Freezing Media and were value- as signed against a calibrator (quantified by counting with a hemacytometer) using the Roche Light Cycler™ Control Beta-Globin test.
A. Method I (usin2 exemplary bulking a2ent)
[0038] An incubator was set to 45°C. 1 % agarose was prepared and allowed to come to 45°C in the incubator. Human red blood cells (RBCs) were spun down in a microcentrifuge at maximum speed. The RBC's were washed with DMEM and the wash was repeated until the lysed cells were removed. The cells were spun down and 4g of RBC's were mixed with 6 mL of DMEM. An appropriate amount of cells containing the KRAS G12C mutation was measured gravimetrically into a sterile cup. The cells were mixed with wild-type cells (that do not contain the KRAS G12C mutation) with a mutant cell percentage of 10%. Two (2) mL of fixed cells containing the KRAS G12C (test cells plus wild-type cells) were mixed with 3 mL of a RBC mixture (0.4 g of RBC cells per mL of DMEM). The cellular mixture was warmed for 20 min. to 45°C. 0.5 mL of the agarose (at 45°C) was mixed with the cellular mixture (the fixed cells and RBCs) and poured into a tissue mold. The tissue mold was placed at -20°C for 7 minutes to quickly solidify the agarose/cellular mixture. The tissue mold was then placed in a refrigerator at 2-8 °C overnight. The next day, the cylinder was cut into minicylinders and processed following the FFPE manufacturing procedure (the 70% alcohol step was performed for 1 nr.) then embedded. The fixed mini-cylinders were transferred into labeled tissue cassettes. The tissue cassettes were transferred into a container filled with 70% alcohol and incubated for a minimum of 1 hour. The alcohol was decanted and excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely. The tissue cassettes were then transferred into a container filled with 95% alcohol and incubated for 1 hour. The alcohol was decanted and excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely. The tissue
cassettes were then transferred into a container filled with 100% alcohol and incubated for 1 hour. The alcohol was decanted and the excess removed using absorbent paper but the tissue cassettes were not allowed to dry completely. The tissue cassettes were transferred into a container filled with Safeclear™ and incubated for 30 minutes. The Safeclear™ was decanted and excess removed using absorbent paper. The tissue cassettes were not allowed to dry completely. The tissue cassettes were transferred into a container filled with a 1 : 1 mixture of Safeclear™ and melted paraffin and incubated for 30 minutes at 65 °C. The 1 : 1 mixture of Safeclear™ and melted paraffin was decanted into a waste container. The tissue cassettes were transferred into container filled with melted paraffin and incubated for 1 hour at 65°C. The melted paraffin was decanted into a waste container. The tissue cassettes were then transferred into a container filled with melted paraffin and incubated for 2 hours at 65 °C. The fixed mini-cylinders were then transferred into a tissue mold containing melted paraffin. The base of the tissue cassette was placed over the tissue mold and paraffin was dispensed from the paraffin-embedding instrument until the mold and cassette were filled. The filled tissue mold was placed onto the refrigerated unit of the paraffin-embedder and allowed to harden for at least 1 hour. The FFPE blocks were sectioned on a Microtome into the appropriate thickness. The section was transferred using forceps into a sterile tube.
B. Method II
[0039] This method was carried out in an identical manner to method I except that the exemplary bulking agent (RBCs) were not added to the cells. The stocks used for in this prior method were also diluted prior to freezing.
Example 2
Comparison Studies
[0040] Four cylinders of KRAS G12C cells and 10% wild-type cells were manufactured using the method I of Example 1A. Ten to 15 blocks were manufactured from each cylinder. The method was found to improve the consistency and ease of handling the FFPE materials. The original cylindrical shape of the synthetic material was better retained. The shape was more consistent, which improved uniformity from section to section. Improving uniformity of the shape also increased the yield of the sections per block. These observations are illustrated in FIGS. 1 and 2 show that the sections with the red blood cells retained the cylindrical shape and were easier to see as compared to the sections that did not contain the red blood cells. In FIG. 1A, the block was manufactured without red blood cells, while the
block on in FIG. IB was manufactured at the same concentration using red blood cells. The block on the right retained the cylindrical shape, while the block on the left did not. FIG. IB shows that during the process of FFPE (and/or DNA or RNA extraction), inclusion of the exemplary bulking agent (RBCs) made it easier to see the cell-containing portion of the block. FIG. 2 shows the section without red blood cells on the left and the section without red blood cells on the right during deparaffinization. SafeClear was added to the sections for deparaffinization. The section including the exemplary bulking agent (RBCs) was found to be easier to see, making the extraction process easier for users. Due to better visibility of the tissue, this also improved the ease of sectioning (e.g., for manufacturing of FFPE controls) as it was easier to see when one had sectioned through the paraffin and reached a full section of tissue. Furthermore, the ease of extraction was improved because it was easier to see the section of cells during deparaffinization.
[0041] Sections were cut from blocks, DNA was extracted therefrom, and the DNA amplified using the TaqMan Mutation Detection Assays (castPCR™ assays) for the KRAS G12C and wild-type alleles performed. The values obtained were substituted into the following formula:
100%
Mutant %— JL / 5 ^ * i M ~™ t i U ····
JL ώ " - vv -^ * ~ > { - i
CTMT = Mean Mutant CT
CfWT = Mean Wild Type CT
f = Normalization factor
CT is an abbreviation for cycle threshold, which describes the cycle number in qPCR when the fluorescence crosses a defined threshold (see, e.g., U.S. Patent Nos. 6,303,305; 6,503,720; 6,783,934, 7,228,237 and U.S. Application No. 2004/0096819). In general, it is expected to see a lower CT value for a sample with higher starting concentration because it will take less PCR cycles for the sample to amplify and reach the defined threshold. By comparing the mutant CT value and wild- type CT value (with normalization), it is possible to compare the relative level of mutant vs. wild-type and calculate the mutant % of the sample. As shown in Table 6, the mutant percentage (see right most column) was very similar for both the new (Example 1A) and prior methods (Example IB).
Table 6
Comparison of Methods
Outlier removed
[0042] Each column in Table 6 represents a step for calculating the mutant %. Thus, this data shows that the inclusion of an exemplary bulking agent (RBCs) did not affect the quality of the DNA in the sample as shown using PCR.
Example 3
Kit for Analysis of KRAS FFPE assay quality control
[0043] There are known mutations within the codon 12 and 13 of the KRAS gene that results in the loss of effectiveness of pharmaceutical therapies. Seven mutations (G12D, G12V, G12C, G12S, G12A, G12R, G13D) comprise 98.5% of known KRAS mutations that have an impact. Cell lines for these mutations are obtained and mixed in defined ratios with red blood cells. A cell line that is wildtype for KRAS can be included as a control.
[0044] A KRAS FFPE kit is prepared containing controls intended for use in assessing the performance of nucleic acid test procedures for the determination of KRAS mutations using the methods in Examples 1 and 2 (see Table 6; 1 vial per KRAS mutation and 1 wildtype (negative control)). Routine use of the KRAS FFPE controls enables laboratories to monitor day-to-day assay variation, lot-to-lot performance of assay reagents, and operator variation. The KRAS FFPE controls can also assist in identifying increases in random or systematic error in testing systems. The KRAS FFPE Controls kit contains controls for the seven major KRAS mutations and a wild type control. Each individual control consists of KRAS mutation-positive cells mixed with the RBC bulking agent that has been formalin-fixed and paraffin-embedded and sectioned to 10 microns thick. The KRAS FFPE Controls are
designed to meet the need for controls for molecular testing of KRAS in FFPE samples. The independent set of external controls helps to ensure that KRAS nucleic acid testing procedures are consistent across manufacturers, testing laboratories, operators, platforms and assay formats. The KRAS FFPE Controls are formulated to mimic formalin fixed paraffin embedded tissues and designed to monitor all procedural steps in extracting human DNA from FFPE. The intact human cells allow for the verification of effective DNA extraction and purification. KRAS test methodology includes an extraction step that releases the DNA for amplification and detection, as appropriate to the test.
Table 7
KRAS FFPE control kit
Example 4
Kit for Analysis of EGFR FFPE assay quality control
[0045] An EGFR FFPE kit is prepared containing controls intended for use in assessing the performance of nucleic acid test procedures for the determination of EGFR mutations using the methods in Examples 1 and 2. Routine use of the EGFR FFPE controls enables laboratories to monitor day-to-day assay variation, lot-to-lot performance of assay reagents, and operator variation. The EGFR FFPE controls also assist in identifying increases in random or systematic error in testing systems. The EGFR FFPE Controls kit contains controls for 29 major EGFR mutations that are associated with drug resistance to chemotherapy drugs and a wild type sequence (see Table 7 for mutations). Each individual control consists of EGFR mutation-positive cells admixed with red blood cells and formalin- fixed and paraffin-embedded and sectioned to 10 microns thick. An EGFR wildtype cell control can be included also. The EGFR FFPE Control meets the need for controls for
molecular testing of EGFR in FFPE samples. The kit contains 29 slices containing mixtures of EGFR mutations in a background of red blood cells and 1 slice containing an EGFR wildtype cell in a background of red blood cells. The independent set of external controls helps to ensure that EGFR nucleic acid testing procedures are consistent across manufacturers, testing laboratories, operators, platforms and assay formats. The EGFR FFPE Controls are formulated to mimic formalin fixed paraffin embedded tissues and are designed to monitor all procedural steps in extracting human DNA from FFPE. The intact human cells allow for the verification of effective DNA extraction and purification. EGFR test methodology includes an extraction step that releases the DNA for amplification and detection, as appropriate to the test.
Table 8
Somatic EGF-R Mutations
Mutation Exon Base Change Cosmic ID
T790M 20 2369C>T 6240
L858R 21 2573T>G 6224
L861Q 21 2582T>A 6213
S768I 20 2303G>T 6241
G719A 18 2156G>C 6239
G719S 18 2155G>A 6252
G719C 18 2155G>T 6253
Insertions 20 2307_2308ins9 12376
2319_2320insCAC 12377
2310_2311insGGT 12378
Deletions 19
2235_ _2249dell5 6223
2235_ _2252>AAT (complex) 13551
2236_ _2253dell8 12728
2237_ _2251dell5 12678
2237_ _2254dell8 12367
2237_ _2255>T (complex) 12384
2236_ _2250dell5 6225
2238_ _2255dell8 6220
2238_ _2248>GC (complex) 12422
2238_ _2252>GCA (complex) 12419
2239_ _2247del9 6218
2239_ _2253dell5 6254
2239_ _2256dell8 6255
2239_ _2248TTAAGAGAAG>C
(complex) 12382
2239_2258>CA (complex) 12387
2240_2251dell2 6210
2240_2257dell8 12370
2240_2254dell5 12369
2239_2251>C (complex) 12383
(Note: the cosmic IDs are taken from the Catalogue of Somatic Mutations in Cancer web site s anger . ac . uk/genetic s/C GP/co smic/) .
Example 5
Manufacturing protocol for sectioning of FFPE blocks
[0046] A procedure for manufacturing FFPE Blocks is described in this example. A sterile cup is filled to the 80ml line with 10% Neutral Buffered Formalin and swirled until all mini- cylinders (the slices) have separated. The mini-cylinders are placed in 10% Neutral Buffered Formalin for 2 hours at room temperature in the shaker set at 125 RPM, labeled and lidded. The 10% Neutral Buffered Formalin is decanted into the appropriate waste container and the mini-cylinders poured into a sterile Petri dish base. The tissue cassette is placed onto the sterile lid of the Petri dish and mini-cylinders transferred into tissue cassettes. A maximum of the same four mini-cylinders could be placed into one tissue cassette. The lid is closed and tissue cassettes placed into an appropriate container with 70% Alcohol. The volume of the 70% Alcohol reached above the tissue cassettes. A minimum fill at the 80ml line of the disposable sterile cup is required. It is incubated for a minimum of 1 hour with a maximum of 24 hours. For a hold time of 1 hour, it is incubated at room temperature. Any hold times that exceeded one hour would be incubated at 2-8°C. 70% Alcohol is decanted into a dedicated waste container. The Container is inverted and tissue cassettes are poured over an absorbent paper. The tissue cassettes are transferred into an appropriately- sized container with 95% Ethanol (ensure that the volume of the 95% Ethanol reaches above the tissue cassette). A minimum of approximately 80mL of 95% Ethanol is required. It is incubated for 55 to 65 minutes at room temperature. The Paraffin Embedder Instrument is turned on. An appropriate amount of paraffin is in each reservoir. The incubator/shaker is turned on and temperature set at 65°C. Clean sterile Polypropylene containers are filled with Paraffin until it reaches the top opening and placed in an incubator shaking at 125 RPM. 95% Alcohol was decanted into an appropriate waste container. The container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry). The tissue cassettes are transferred into an appropriately sized container with 100% Ethanol (ensuring that the volume of the 100% Ethanol reaches above the tissue cassette) and incubated between 60 to 80 minutes at Room Temperature. A minimum of
approximately 80mL of 100% Ethanol is required. The 100% Alcohol is decanted into an appropriate waste container. The container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry). The tissue cassettes are transferred into an appropriately sized container with 100% Ethanol (ensuring that the volume of the 100% Ethanol reaches above the tissue cassette) and incubated between 30 to 40 minutes at Room Temperature. The 100% Alcohol is decanted into a sink with running water. The container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry). The tissue cassettes are transferred into an appropriately sized container with SafeClear™ and the volume of the SafeClear™ made to reach above the tissue cassette and incubated between 30 to 40 minutes at room temperature. The SafeClear™ is decanted into a sink with running water. The container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry). The tissue cassettes are placed into an appropriate container with SafeClear™, ensuring that the volume of the SafeClear™ reaches above the tissue cassette. The tissue cassettes are incubated between 30 to 40 minutes at room temperature. The incubator/shaker was set at 65 °C, ensuring that the shaker switch is in the OFF position. Equal volumes of melted paraffin were added with SafeClear and placed in a 65 °C + 1 °C incubator. The container with the tissue cassettes is inverted and tissue cassettes poured over an absorbent paper (without allowing the tissue cassettes to dry). The tissue cassettes are transferred into an appropriate container with 50:50 Paraffin/SafeClear™, ensuring that the volume of the 50:50 Paraffin/SafeClear™ reaches above the tissue cassette, and incubated between 30 to 40 minutes at 65 °C + 1 °C. (Ensuring the Shaker switch is in the OFF position). The 50:50 Paraffin/SafeClear™ was decanted into a disposable container. The tissue cassette was transferred into an appropriate container with Paraffin (ensuring that the volume of the Paraffin reaches above the tissue cassette), and incubated between 60 to 80 minutes at 65 °C + 1 °C. The Shaker switch is in the OFF position. The Paraffin was decanted into a disposable container. The tissue cassette was transferred into an appropriate container with Paraffin (Ensure that the volume of the Paraffin reaches above the tissue cassette), and incubated between 60 to 80 minutes at 65 °C + 1 °C (Ensure Shaker switch is in the OFF position). The Paraffin is decanted into a disposable container. The tissue cassette is transferred into an appropriate container with sample reservoir of the Paraffin Embedder (ensuring that the volume of the Paraffin reaches above the tissue cassettes) and incubated between 120 to 140 minutes.
[0047] Paraffin embedding is performed as described herein. After incubation, the first tissue cassette is removed and placed on a paraffin embedder. Tissue molds are placed into the warmed tissue mold holder. Mini-cylinders are inspected to ensure that they are intact and have significantly shrunk in size. The tissue mold is removed from the tissue mold warmer and paraffin dispensed from a nozzle to fill the bottom of the well. The tissue mold containing paraffin is placed over the cold portion of the paraffin embedder. In a timely manner, a mini-cylinder is placed onto the center of the tissue mold and allowed to cool partially, but not until solid. The tissue cassette is placed without the lid over the tissue mold with the flat surface facing the tissue. The tissue cassette is placed downward (ensure that no air bubbles are trapped within the sample). If air bubbles are present, the tissue cassette is lifted and placed back down until all the air bubbles are removed (ensure that the mini- cylinder is still within the center of the tissue mold). Paraffin is dispensed from the nozzle until the entire bottom of the tissue cassette is covered. Material is carefully transferred and placed on the cold side of the paraffin embedder. This is repeated until all of the mini- cylinders are embedded in paraffin. The embedded cylinders are allowed to cool for a minimum of 30 minutes up to a maximum of 24 hours on the cold side of the embedder. If the material is going to be filled within the next 24 hours, the bulk material is stored at 2-8°C until filled. If the material is not going to be filled within the next 24 hours, the bulk material is stored at the appropriate storage temperature.
Example 6
Additional Comparison Studies
[0048] These procedures may also be used to assay markers of unknown significance or known, but experimental (e.g., not diagnostic), significance (e.g., for basic research purposes). For example, cells expressing any marker of interest may be used in place of and / or in addition to luciferase-expressing cells and assayed as desired. Multiple (e.g., four) cylinders containing cells where about 90% of such cells are engineered to express luciferase and about 10% are "wild-type" cells (e.g., do not express luciferase) are manufactured using the methods of Examples 1 A and 2 using the exemplary bulking agent RBCs. Multiple (e.g., 10-15) blocks are manufactured from each cylinder. Sections are cut from blocks, DNA extracted, and the DNA amplified using the TaqMan Mutation Detection Assays (castPCR™ assays) for the luciferase and wild-type sequences. The luciferase percentage is then calculated using the procedure described in Example 2. This system is useful for basic
research purposes as cells expressing any sequence of interest may be used in place of the luciferase-expressing cells.
[0049] Each embodiment disclosed herein may be used or otherwise combined with any of the other embodiments disclosed. Any element of any embodiment may be used in any embodiment. Although the invention has been described with reference to specific embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the true spirit and scope of the invention. In addition, modification may be made without departing from the essential teachings of the invention.
Claims
1. A method for preparing a formalin-fixed, paraffin-embedded sample, the method
comprising combining test cells with a bulking agent having a physical differentiating feature from the test cells to provide a test mixture; and preparing a formalin-fixed, paraffin-embedded sample comprising the mixture.
2. The method of claim 1 wherein the bulking agent improves the visibility and / or
uniformity of the test cells in the sample as compared to a sample prepared in the absence of the bulking agent.
3. The method of claim 1 or 2 wherein the bulking agent comprises particles having a
physical differentiating feature from the test cells.
4. The method of claim 3 wherein the particles are substantially the same size as the test cells.
5. The method of claim 1 wherein the particles are control cells.
6. The method of any one of claims 1-5 wherein the physical differentiating feature is color.
7. The method of claim 6 wherein the color is provided by a detectable label.
8. The method of claim 7 wherein the detectable label is fixably attached to the particles.
9. The method of any one of claims 3-8 wherein the particles do not comprise a nucleus.
10. The method of any one of claims 3-9 wherein the particles do not comprise nuclear DNA.
11. The method of any one of claims 3-10 wherein the particles do not comprise RNA.
12. The method of claim 11 wherein the RNA is microRNA (miRNA) or messenger RNA (mRNA).
13. The method of claim 1 wherein the test cells comprise a genetic marker not detectable and / or not present in the bulking agent.
14. The method of claim 13 wherein the bulking agent consists essentially of control cells.
15. The method of any one of claims 1-14 wherein the bulking agent comprises red blood cells.
16. The method of any one of claims 1-15 wherein the test mixture comprises about 10"8 to about 99.99999999% bulking agent.
17. The method of any one of claims 1-16 wherein the test mixture comprises test cells, control cells and bulking agent.
18. The method of any one of claims 1-17 further comprising detecting the marker on the test cells.
19. The method of claim 18 wherein the detecting step is carried out using a nucleic acid amplification and detection assay system.
20. A formalin-fixed, paraffin-embedded sample prepared by a method of any one of claims 1-17.
21. A kit comprising a sample of claim 20.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/034,617 US20160313224A1 (en) | 2013-11-05 | 2014-11-05 | Method for Preparing FFPE Quality Control Material with Bulking Agent |
EP14802752.7A EP3066194B1 (en) | 2013-11-05 | 2014-11-05 | Method for preparing ffpe quality control material with bulking agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361900266P | 2013-11-05 | 2013-11-05 | |
US61/900,266 | 2013-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015069791A1 true WO2015069791A1 (en) | 2015-05-14 |
Family
ID=51952013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/064162 WO2015069791A1 (en) | 2013-11-05 | 2014-11-05 | Method for preparing ffpe quality control material with bulking agent |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160313224A1 (en) |
EP (1) | EP3066194B1 (en) |
WO (1) | WO2015069791A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017053683A1 (en) * | 2015-09-24 | 2017-03-30 | Microgenics Corporation | Formalin fixed paraffin embedded (ffpe) control reagents |
EP3384054A4 (en) * | 2015-12-01 | 2019-07-24 | Seracare Life Sciences, Inc. | Multiplex cellular reference materials |
CN111057768A (en) * | 2020-01-20 | 2020-04-24 | 菁良基因科技(深圳)有限公司 | Preparation process of lung cancer and colorectal cancer gene mutation paraffin embedding reference substance |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11300486B1 (en) * | 2016-11-23 | 2022-04-12 | Array Science, Llc | Apparatus for producing high yield cores for use in a microarray block, method for using same |
US11460400B2 (en) | 2020-07-07 | 2022-10-04 | Sakura Finetek U.S.A., Inc. | Use of IR spectroscopy to evaluate penetration of reagents into biological specimen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012022557A1 (en) * | 2010-08-17 | 2012-02-23 | Siemens Healthcare Diagnostics Inc. | Reference sample for quality control in molecular diagnosis |
US20120088233A1 (en) * | 2010-10-12 | 2012-04-12 | Life Technologies Corporation | Method of Preparing Quality Control Material for FFPE |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955848B2 (en) * | 2006-04-03 | 2011-06-07 | Trustees Of Dartmouth College | MicroRNA biomarkers for human breast and lung cancer |
US9589099B2 (en) * | 2011-07-21 | 2017-03-07 | The Chinese University Of Hong Kong | Determination of gene expression levels of a cell type |
-
2014
- 2014-11-05 US US15/034,617 patent/US20160313224A1/en not_active Abandoned
- 2014-11-05 WO PCT/US2014/064162 patent/WO2015069791A1/en active Application Filing
- 2014-11-05 EP EP14802752.7A patent/EP3066194B1/en not_active Not-in-force
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012022557A1 (en) * | 2010-08-17 | 2012-02-23 | Siemens Healthcare Diagnostics Inc. | Reference sample for quality control in molecular diagnosis |
US20120088233A1 (en) * | 2010-10-12 | 2012-04-12 | Life Technologies Corporation | Method of Preparing Quality Control Material for FFPE |
Non-Patent Citations (1)
Title |
---|
KATIE L PITTS ET AL: "High speed versus pulsed images for micro-particle image velocimetry: a direct comparison of red blood cells versus fluorescing tracers as tracking particles", PHYSIOLOGICAL MEASUREMENT, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 34, no. 10, 18 September 2013 (2013-09-18), pages 1363 - 1374, XP020251552, ISSN: 0967-3334, [retrieved on 20130918], DOI: 10.1088/0967-3334/34/10/1363 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017053683A1 (en) * | 2015-09-24 | 2017-03-30 | Microgenics Corporation | Formalin fixed paraffin embedded (ffpe) control reagents |
GB2559898A (en) * | 2015-09-24 | 2018-08-22 | Microgenics Corp | Formalin fixed paraffin embedded (FFPE) control reagents |
GB2559898B (en) * | 2015-09-24 | 2019-12-11 | Microgenics Corp | Formalin fixed paraffin embedded (FFPE) control reagents |
EP3384054A4 (en) * | 2015-12-01 | 2019-07-24 | Seracare Life Sciences, Inc. | Multiplex cellular reference materials |
CN111057768A (en) * | 2020-01-20 | 2020-04-24 | 菁良基因科技(深圳)有限公司 | Preparation process of lung cancer and colorectal cancer gene mutation paraffin embedding reference substance |
CN111057768B (en) * | 2020-01-20 | 2023-11-03 | 菁良科技(深圳)有限公司 | Preparation process of paraffin embedded reference for gene mutation of lung cancer and colorectal cancer |
Also Published As
Publication number | Publication date |
---|---|
EP3066194A1 (en) | 2016-09-14 |
EP3066194B1 (en) | 2019-08-07 |
US20160313224A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9909964B2 (en) | Method of preparing quality control material for FFPE | |
AU2021229232B2 (en) | Transposition into native chromatin for personal epigenomics | |
US20220154288A1 (en) | Combined analysis of cell-free nucleic acids and single cells for oncology diagnostics | |
Laget et al. | Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion | |
EP3066194B1 (en) | Method for preparing ffpe quality control material with bulking agent | |
Lianidou et al. | Circulating tumor cells and circulating tumor DNA | |
Zhang et al. | Molecular analysis of DNA in blastocoele fluid using next-generation sequencing | |
Babu et al. | 3D genome organization in health and disease: emerging opportunities in cancer translational medicine | |
Decordier et al. | Phenotyping for DNA repair capacity | |
CN108220392A (en) | Enrichment and the method for determining target nucleotide sequences | |
van den Bos et al. | Quantification of aneuploidy in mammalian systems | |
Smith et al. | Optical genome mapping for structural variation analysis in hematologic malignancies | |
JP6873089B2 (en) | Methods and systems for identifying patient-specific driver mutations | |
Chamorro González et al. | Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells | |
US20220090204A1 (en) | Dna reference standard and use thereof | |
Hoover et al. | A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts | |
Mohanty et al. | Liquid Biopsy, the hype vs. hope in molecular and clinical oncology | |
Lange et al. | Non-coding variants in cancer: mechanistic insights and clinical potential for personalized medicine | |
Shegekar et al. | The emerging role of liquid biopsies in revolutionising cancer diagnosis and therapy | |
Poremba et al. | Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer | |
Caburet et al. | Combing the genome for genomic instability | |
JP2021531824A (en) | Use of Droplet Single Cell Epigenome Profiling for Patient Stratification | |
Johnson et al. | Preclinical models and resources to facilitate basic science research on malignant mesothelioma–a review | |
WO2020218554A1 (en) | Digital somatic cell variation analysis | |
Ioannidis et al. | Profiling of MicroRNAs in the biofluids of livestock species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14802752 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15034617 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014802752 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014802752 Country of ref document: EP |